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The cessation of bleeding in mammals occurs due to a well-conserved sequence of 
protein activation known as the coagulation cascade.  However, people who have a 
deficiency in one or more proteins in this cascade, whether due to genetics or blood loss, 
struggle to maintain hemostasis. In order to aid patients in the restoration of hemostasis, 
exogenous proteins are often administered in response to bleeding events.  However, 
these proteins are limited and costly due to limited supply of donor blood available for 
the production of plasma-derived proteins and the high cost of mammalian cell bio-
reactors required for the production of recombinant proteins.  As an alternative to the two 
previously aforementioned methods, human recombinant coagulation proteins have also 
been produced in the mammary gland of mice, swine, and bovine.  This technique offers 
high production of active coagulation protein at low scaled-up cost.  The research in this 
dissertation details the preclinical trials and characterization of two such proteins, factor 
IX produced in swine (FIX) and fibrinogen produced in bovine (FI), as well as one 
traditional recombinant protein, factor XIII produced in Pichia pastoris (FXIII).  FXIII 
and FI, in addition to thrombin, are the main components of fibrin sealant, which is 
 typically used to seal a wound in the case of a catastrophic bleeding event.  FIX is used in 
a completely different context: the treatment of hemophilia B, a disease where the body 
produces no active FIX.  Pharmacokinetic analysis and characterization of FIX were 
performed both intravenously and buccally in mice and dogs.  The analysis revealed that 
FIX produced in the mammary gland of swine exhibited enhanced endothelial binding 
while maintaining normal whole blood clotting times despite the reduced plasma 
retention times.  FIX stored in the extravascular reservoir was shown to influence FIX 
retention times for samples infused over 24 hours after plasma levels had been depleted.  
FXIII produced in yeast was shown to be monomeric and containing an artificial 
activation peptide that enhanced the crosslinking of fibrinogen with a reduced activation 
time lag. 
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Chapter 1:         
Introduction 
 
1.1  Background 
The coagulation cascade [1, 2], as seen in Figure 1.1, is the primary method for 
maintaining hemostasis in most mammalian organisms.  This delicate cycle reacts to the 
presence of tissue factor, which comes into contact with the coagulation proteins after 
vascular injury, in order to trigger a chain reaction of serine proteases, transglutaminases, 
tenase complexes, and glycoproteins [1].   This reaction terminates with the formation of 
a cross-linked fibrin mesh which holds together a thrombus containing platelets, collagen, 
red blood cells, and fibroblast [2].  However, even after the thrombus is formed, 
degradation steps for many of the coagulation proteins must occur in order to prevent the 
creation or buildup of thrombi in the circulatory system.  Proteins such as protein C [3], 
antithrombin [4], and plasmin [5] are responsible for preventing runaway coagulation 
reactions by degrading activated coagulation factors in the bloodstream in addition to the 
removal of fibrin scaffolds as wound healing progresses. 
 Unfortunately, this cycle of activation, inactivation, and degradation can be 
disrupted in many ways.  The most direct and common method for coagulation factor 
depletion is in the case of catastrophic blood loss.  In this case, the loss of platelets which 
contain key elements of the coagulation cascade and coagulation factors contained in the 
plasma preclude the restoration of hemostasis by native thrombus formation.  Hospitals 
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combat scenarios such as these by administering coagulation factors and artificial 
scaffolds both topically and intravenously.  
 
Figure 1.1. Intrinsic and Extrinsic Pathways of the Coagulation Cascade.  Recombinant versions of the 
proteins with boundaries are the focus of this dissertation.  Adapted from Davie et al. [1]  
 
Genetics and immune malfunctions can also play a role in the depletion of one or 
more coagulation factor.  Diseases such as Hemophilia A [6], Hemophilia B [6], and von 
Willebrand [7] disease manifest when levels of a specific protein are either not produced 
by the body due to a genetic abnormality, which is often hereditary, or are removed from 
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the body by the development of autoantibodies.  Treatment of these diseases, depending 
on the severity, can currently be a lifelong and costly procedure.  In addition, patients 
who do not produce one of these proteins natively and rely on the prophylactic infusions 
have an increased risk of autoantibody development, which can exponentially increase 
the cost of an already costly treatment [8].  Traditionally, prophylactic treatment of these 
diseases had been delivered using purified proteins from donor plasma.  However, with 
the limited supply of donor plasma available for pharmaceutical use and the increased 
awareness of the risk of blood-born viral infection, efforts were made in the 1970s and 
1980s to develop recombinant techniques for producing pharmaceutical proteins.  It was 
quickly established that basic bacterial bioreactors did not provide proper post 
translational modifications (PTM) for many proteins, and as a result, higher order 
organisms such as yeast and bovine have been modified to produce high yields of 
proteins with PTM similar to their respective endogenous human protein [9-11]. 
1.2 Fibrinogen 
Fibrinogen (FI), through its activated form fibrin, forms the foundation of the 
mesh that holds a thrombus together in the event of an injury [12, 13].  This foundation is 
formed by both the crosslinking of fibrin fibers and the attachment of fibrin to key 
components such as platelets (Figure 1.2).  These fibrin fibers are formed when FI 
encounter thrombin (FIIa), the activated form of prothrombin, and they are crosslinked by 
the transglutaminase factor XIII (FXIII) to form a fibrin scaffold [12].  During wound 
healing, this scaffold serves as a pathway for the migration of macrophages, fibroblasts, 
and neutrophils in addition to aiding in native cell migration and proliferation [14].  As 
wound healing nears completion, exposed fibrin sites activate plasminogen into plasmin, 
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which breaks down the fibrin scaffold allowing for the complete restoration of native 
cells [13]. 
 
Figure 1.2. Schematic of fibrinogen activation into fibrin by thrombin in the presence of factor XIII. 
FI forms double-stranded fibrin protofibrils when exposed to both FXIII and FIIa.  These protofibrils are 
capable of crosslinking laterally to form a fibrin mesh. Adapted from Mosesson [13]. 
 
On a molecular level, FI is a 340 kDa glycoprotein produced by hepatocytes and 
assembled in the endoplasmic reticulum (ER).  The assembled structure contains two α-
chains, two β-chains, and two γ-chains.  Two major variants of FI exist, each containing 
either one or two altered γ-chains (γγ’ or γ’γ’).   The γ’-chain contains a substitution of 20 
amino acids in place of γ-chain 408-412 [13].  This change in the γ-chain induces binding 
of activated FI to FXIII and FIIa, sequestering them into the hemostatic plug[15].  These 
variants form a minor subpopulation of the total FI concentration with approximately 8% 
of γ-chains population being γ’-chains [13].  The γγ’ variant is more common than the 
γ’γ’ variant, the former corresponding to 15% of the total FI population while the latter 
accounts for less than 1% of the total FI population [13].    
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Fibrinogen deficiency is a rare disease (1:1,000,000 people have been diagnosed 
with the most severe form of the disease) wherein the body does not produce functional 
FI [16].  Prophylactic measures similar to hemophilia are used to treat the disease.  FI has 
also be found to be useful as secondary form of treatment in patients with a high risk of 
bleeding and in patients who are currently or have recently suffered from severe blood 
loss [17]. As a result of these factors, there are several commercial ways to obtain FI.  
Fresh-frozen plasma is occasionally administered despite its low concentration of FI, but 
modern targeted treatments for FI deficiency typical rely on cryoprecipitates and FI 
concentrates [17].  At the time of writing this dissertation, there are four commercial FI 
concentrates from plasma sources currently available; however, only one is available for 
medical use in the USA [18].  In contrast, cryoprecipitate is widely available in the USA 
and UK, but not available in most EU countries [17]. 
 
1.3 Factor XIII 
FXIII is also activated by FIIa in the presence of calcium to form the activated 
species FXIIIa.  FXIIIa is the last enzymatic step in the coagulation cascade and is 
responsible for covalently crosslinking the α-chains and γ-chains of FI in an antiparallel 
fashion, resulting in a stronger, insoluble fibrin clot that is resistant to fibrinolysis [19, 
20].  The γ-γ chain crosslinking is kinetically favored and is completed within 10 minutes 
of interaction, while α-γ crosslinking is a slower process, taking up to one day, that 
solidifies and stabilizes the fibrin mesh [21-23].  Fully-formed plasma FXIII has a 
molecular weight (MW) of approximately 326 kDa and contains two α-chains (75 kDa) 
and two β-chains (88 kDa) [24].  However, FXIII that is stored on platelets loses the two 
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β-chains while maintaining all catalytic activity [24].  This has led to the conclusion that 
the β-chains acts primarily as a stabilizing agent in plasma, preventing non-specific 
activation and transporting the α-chains after expression from monocytes, 
megakaryocytes, and hepatocytes [25-28]. 
 
1.4 Factor IX  
Factor IX (FIX) is a vitamin-dependent protein traditionally thought of as a key 
component in the intrinsic pathway of the coagulation cascade; however, recent research 
has revealed that FIX also has a key role in extrinsic pathway [1, 29].  The intrinsic 
pathway of FIX activation into FIXa involves activated factor XI (factor XI) in the 
presence of calcium.   The extrinsic pathway of FIX was found when systems containing 
no factor XI or factor XII [30] were found to coagulate much faster than systems 
containing no factor IX.  Further research determined that factor IX was also able to be 
activated by factor Xa (FXa) and played a key role in both the intrinsic and extrinsic 
pathways by the formation of a FIXa/factor VIIIa (FVIIIa) tenase complex [31]. 
Molecularly, FIX is a 56 kDa serine protease made up of one vitamin K-
dependent γ-carboxyglutamic (Gla) domain, two epidermal growth factor (EGF)-like, and 
one catalytic domain [32, 33].  The catalytic domain contains the active site responsible 
for cleavage of FXa and acts in parallel to the second EGF-like domain to form the tenase 
complex with FVIIIa [34, 35].  The Gla domain is responsible for binding FIX to the 
extracellular matrix (ECM) in a sequestration phenomenon which is currently being 
researched [36].  It is known that the Gla domain of fully carboxylated FIX contains 12 
potential Gla residues which play a large role in the tertiary structure of the Gla domain 
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and consequently the binding of FIX to the ECM [37].  Also playing a role in tertiary 
structure are magnesium and calcium concentrations.  FIX contains a total of 10 divalent 
metal sites, which at physiological conditions contain six calcium-dependent sites, three 
magnesium-dependent sites, and one non-specific site [38, 39].  
 
1.5 Fibrin Sealants 
  Fibrin sealants (FS) have been researched by the medical community for use in 
wound healing since the early 1900s, but the first mass-produced commercial FS only 
became available the 1970s [5, 40].  While FI is considered the most prominent 
component contained in FS, almost all FS contain additional proteins from the 
coagulation cycle.  Additionally, calcium is included in all fibrin sealants as a necessary 
component for timely coagulation.  FIIa is included in all major FS as an activation step; 
however, the inclusion of FIIa necessitates a dual-syringe or similar dual-storage 
container delivery device.  This is due to the decrease in solubility of FI as it activates 
into fibrin monomer.  The fibrin monomer created by this activation is capable of 
jamming medical application devices due to the high activity FIIa, and it is therefore 
essential that FIIa and FI be delivered separately to the wound site, with disposable 
equipment, or mixed in transport to the wound site [40].  FXIII and aprotinin are also 
commonly included in FS formulations for their clot strengthening and antifibrinolytic 
properties respectively [41]. 
 FS provides a native hemostatic agent capable of both sealing wounds and 
encouraging the proliferation of native wound healing.  The Food and Drug 
Administration (FDA) has approved commercially available FS for use as a hemostat, for 
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all surgeries; a sealant, for surgeries such as colostomy closure; and as an adhesive, for 
attaching skin grafts to burns [42].  There are records of additional off-label uses of FS 
such as tissue engineering and drug delivery that have been documented in literature [42].  
Unfortunately, most FS are currently produced using plasma-derived material, which 
inherently contain a risk for virus transmission and due to limitations on supply remain 
economically unfeasible for most commercial purposes [43]. 
 
1.6 Hemophilia 
Hemophilia is a hereditary genetic disorder wherein a patient is unable to produce 
active FVIII (hemophilia A) or FIX (hemophilia B), and treatment for the disorder can 
cost over 100,000 USD per annum in severe cases [44]. This cost can increase drastically 
if a patient develops inhibitors to replacement protein after receiving treatment [45].  
Treatment of hemophilia is prescribed in two regimes: on-demand and prophylaxis. On-
demand treatment requires immediate infusions of coagulation proteins when a bleeding 
episode occurs, while prophylaxis requires infusions of coagulation protein 2-3 times per 
week [46].  For severe hemophiliacs over a life-long basis, it has been found that 
prophylaxis provides better health outcomes for a cost equal to on-demand; however, the 
up-front cost nature of prophylaxis makes this option unaffordable for many patients 
[46]. The equivalence in cost for the two treatment regimens is partially due to 
undetected internal bleeding which can damage many types of tissue.  Patients using both 
regimes still often suffer from having inadequate supply of coagulation proteins to 
completely stop internal bleeding, and this can be clearly demonstrated by the large 
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amount of knee, elbow, ankle, and hip replacements required by hemophilic patients [47, 
48]. 
Hemophilia is a relatively rare disease, 1 in 5,000 and 1 in 30,000  male children 
who survive childbirth are affected by hemophilia A and hemophilia B respectively [49]. 
Despite the rarity of the disease, hemophilia has a large economic impact on countries 
that can afford to treat it. Hemophilia is different than most common diseases, as the 
coagulation factors used to treat the disease make up, on average, at least 75% of the 
healthcare cost of a patient [50]. The global market demand in 2002 for recombinant and 
plasma-derived coagulation factors was estimated to be 2 billion USD [50], and 2011 
market research estimates the global demand for hemophilia treatment products to be 8.5 
billion USD [51]. Considering that 70% of the world’s hemophiliacs are underdiagnosed 
or untreated according World Federation of Hemophilia [52], the market for hemophilia 
treatment products has the potential to greatly expand. 
 
1.7 Recombinant Proteins  
In order to circumvent the supply issues and risk factors of plasma-derived 
products, recombinant proteins have been manufactured as an alternative since the 1980s.  
Since 1982 when the FDA approved production of recombinant insulin in Escherichia 
coli [53], recombinant proteins have also been produced in other types of bacteria, yeast, 
plants, mammalian cell bioreactors, and most recently in transgenically modified animals. 
Each production system provides its own unique advantages, from human-like PTM to 
efficient high yields to minimized risk factors. 
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Human coagulation proteins are a target for development of recombinant versions 
due to the limitations on plasma supply.  There are currently many varieties of 
commercially-available, FDA approved recombinant coagulation factors including two 
FIX drugs [54, 55], one FXIII drug [56], and one thrombin drug [57]. All four of these 
drugs were produced in either yeast or a mammalian cell bioreactor. There has been no 
commercially-available, FDA approved recombinant FI approved to date. 
Recombinant human proteins produced by transgenic animals were first approved 
by the FDA in 2009 [58, 59].  This product, antithrombin, was produced in the milk of 
transgenic goats and exemplifies the typical approach for production of recombinant 
proteins in transgenic animals.  The labs of Dr. William H. Velander have begun 
preclinical trials and characterization of two such proteins: transgenic FIX (tg-FIX) 
produced in swine milk [9, 60] and transgenic FI (tg-FI) produced in bovine milk [61].  In 
addition, a recombinant FXIII subunit A (r-FXIIIA1a has been produced in Pichia 
pastoris  to be used alongside tg-FI and commercially available recombinant FIIa [62].  
 
1.8 Dissertation Objectives  
Recombinant coagulation factors provide a treatment approach that does not 
deplete the supply of available plasma, and this dissertation focuses on the 
characterization and preclinical trials of tg-FIX, tg-FI, and r-FXIIIA1a.  The objectives 
for these coagulation factors were as follows: 
1. Pharmacokinetics of tg-FIX delivered intravenously to mice: A 
preliminary study on the efficacy of intravenous tg-FIX was carried out in 
normal, knock-out, and R333Q cross-reactive material positive mice.  
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2. Pharmacokinetics of tg-FIX delivered intravenously to dogs:  tg-FIX was 
evaluated in hemophilia B dogs, the penultimate model before clinical 
trials, for safety and efficacy.  A molecular basis for the pharmacokinetics 
presented was also sought. 
3. Pharmacokinetics of tg-FIX delivered buccally and orally to mice and 
dogs: tg-FIX was administered to both mice and dogs as untreated tg-FIX 
milk and formulated as calcium-phosphate encapsulated FIX in order to 
evaluate the pharmacokinetics of both buccal and oral delivery of FIX. 
4. Characterize the compaction of FIX by divalent metals: FIX was 
characterized for the first time as a zymogen for divalent metal 
compaction using orthogonal methods. 
5. Characterization of r-FXIIIA1: r-FXIIIA1 was produced in Pichia pastoris 
and characterized for structure and function.  The FXIII produced had 
normal activity while presenting with several novel properties not found in 
human FXIII or previously documented FXII produced in yeast.    
6. Characterization of the clot strengthening properties of FXIIIA1: FXIII 
was evaluated ex vivo for clot strengthening properties in FS, human 
whole blood, platelet-poor plasma, and platelet-rich plasma.  FXIII was 
also evaluated as a factor in efficacy of traditional measurements for clot 
strength measurements. 
7. In vivo application of liquid fibrin sealant in the presence of carrier foam: 
Liquid fibrin sealant containing FI, FIIa, and FXIII has been optimized for 
wound sealing in swine hepatic resection models.  
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Each objective has been written as a self-contained chapter for this dissertation. 
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2.1 Abstract 
Hemophilia B is an x-linked disorder caused by a deficiency of coagulation factor 
IX (FIX).  Current replacement therapy for hemophilia B patients comes from two 
sources: factor IX derived from human plasma (pd-FIX) or human recombinant factor IX 
(r-FIX) produced in CHO cell culture bioreactors.  The post-translational complexity of 
FIX governs both its coagulation activity and pharmacokinetic behavior. The use of 
recombinant human factor IX expressed in the milk of transgenic pigs (tg-FIX) is a 
promising alternative because of the high level of expression that can be realized by the 
mammary gland.  Here we investigate the relative pharmacokinetic behaviors pd-, r-, and 
tg-FIX in hemophilia B knockout mice.  The time course of FIX protein, coagulation 
activity, and specific activity levels were followed for recovery and terminal clearance 
phases.  The specific activity of both r-FIX and tg-FIX detected in circulation were 
maintained constant for the first 16 hours of the terminal clearance phase, indicating that 
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the detected circulating FIX was not degraded.  Additionally, tail-cut studies were 
performed on FIX knockout mice infused with r-FIX and tg-FIX.  Mice infused with r-
FIX and tg-FIX had significantly reduced bleeding times compared to untreated mice.  
These preclinical trials hint at the complexity of FIX infusion therapy while establishing 
the safety and efficacy of the tg-FIX. 
 
2.2 Introduction 
Hemophilia B is a bleeding disorder characterized by a deficiency of biologically 
active coagulation factor IX (FIX) [1, 2].  The severity of this condition varies between 
individuals ranging from mild to severe, where severe cases present with coagulation 
activity level of FIX  of less than 1% of the normal activity [3].  In order to maintain 
normal levels of FIX and decrease the occurrence of bleeding episodes, intravenous 
periodic replacement therapy is the recommended treatment for most patients [4].  There 
are currently two commercially available versions factor IX approved for clinical use: 
plasma derived pools (pd-FIX) and human recombinant cell culture bioreactors (r-FIX) 
[4-6].  Despite the creation of r-FIX, the price of treatment for Hemophilia B still remains 
unaffordable or unavailable for many people [7, 8]. 
FIX is a vitamin K-dependent plasma glycoprotein that in its zymogen form is 
found, under normal physiological conditions, at concentration levels of 5 μg/mL (Mr = 
57,000) [9]. The mammary gland has been looked to as a vehicle to manufacture complex 
biomolecules, such as FIX, because of its well-recognized capacity to perform multiple 
post-translational modifications (PTMs) and high levels of expression [10, 11].  Factor IX 
18 
is a prime example of the application of transgenic animals to produce protein due to its 
biological activity being intimately linked to its PTMs [12]. 
We have previously demonstrated the production and purification of recombinant 
human factor IX expressed in the milk of transgenic pigs (tg-FIX) [13, 14].  This tg-FIX 
is comprised of multiple subpopulations of factor IX varying on the degree of γ-
carboxylation in the Vitamin K-dependent γ-carboxyglutamic (Gla) domain [15]. This 
paper aims to demonstrate the safety and efficacy of tg-FIX in cross-reactive material 
negative (CRM-) FIX knockout (FIXKO) mice [16]. 
 
2.3 Materials and Methods 
Unless otherwise indicated, all reagents were analytical or biological grade and 
were obtained from VWR International LLC (Radnor, PA, USA), Thermo Fisher 
Scientific (Waltham, MA, USA) or Sigma (St. Louis, MO, USA).  Reference proteins pd-
FIX (Mononine, CSL Behring, USA) and r-FIX (BeneFIX, Wyeth, USA) were outdated 
for clinical use but displayed full procoagulant activity on reconstitution as per 
manufacturer instructions. 
Purification of tg-FIX 
Whole milk of transgenic pigs containing tg-FIX was mixed with a 100 mM 
solution of ε-aminocaproic acid, 430 mM sodium citrate, and 40 mM benzamidine.  The 
mixture was subjected to ultrafiltration-diafiltration to separate caseins and fat globules 
[13].  The filtrate was loaded into an affinity column (FIXSelect, GTC Biotherapeutics) 
and eluted with 2M MgCl2. The elute was dialyzed against a 10 mM sodium citrate 
solution pH 6.8 and loaded into a Q-Sepharose Fast Flow column that was equilibrated 
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with a 2 mM imidazole buffer solution pH 7.5. The column was washed with 525 mM 
ammonium acetate and the protein eluted with an 800 mM ammonium acetate solution.  
The eluted mixture was dialyzed against a 20 mM imidazole, 50mM NaCl buffer solution 
pH 7.5. 
The dialyzed solution was further purified using a ceramic hydroxyapatite column 
(CHT) equilibrated with a 20 mM imidazole, 50mM NaCl buffer solution pH 7.5.  Then 
it was washed with 1M NaCl, re-equilibrated with a 20 mM imidazole, 50mM NaCl 
buffer solution pH 7.5 and washed with 80 mM potassium phosphate solution.  The 
purified tg-FIX was eluted with a 200 mM potassium phosphate solution. 
The integrity of the purified tg-FIX was verified by standard 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reduced and reduced 
conditions; and Western blot detection using an anti-human factor IX rabbit polyclonal 
(Sigma, St Louis, MO, US) paired with a goat anti-rabbit IgG H&L peroxidase conjugate 
(Sigma, St Louis, MO, US).  The procoagulant activity of the stock protein solutions was 
measured with an activated partial thromboplastin time (aPTT)  assay as previously 
described [14]. 
Clearance studies 
In vivo experiments were performed following institutional guidelines. CRM- 
FIXKO were previously described by Lin et al. [17].  We assumed a plasma 
concentration of 0.9 mL per 20 g of body weight in mice and calculated a target dose 
concentration of 35 μg/mL-plasma and 75 μg/mL-plasma for recovery and terminal 
clearance phase studies, respectively.  FIXKO mice with an average weight of 20 g were 
20 
injected with a solution containing the target concentration of protein via the tail vein for 
each type of pd-, r-, and tg- factor IX.  
Blood samples were collected from the retro-orbital plexus at time intervals of 1, 
5, 10, 15, and 30 minutes post injection (recovery phase) and 0.5, 6, 9, 12, 16, and 24 
hours post injection (terminal clearance phase).  Plasma was separated from blood cells 
by microcentrifugation [18] and stored at -80°C until assayed for protein concentration 
and procoagulant activity at each time point as described before[19]. 
Clearance curves corresponding to the recovery and elimination phase studies 
were constructed for each pd-, r-, and tg- factor IX injected by plotting the mean average 
value of procoagulant activity and its corresponding protein concentration against time.  
Each experimental data set was fitted using two-parameter exponential decay models 
with and without data weighting[20].  The fitting models were compared and the best 
fitting curve selected based on an F-test (P<0.05) of the extra sum-of-squares, goodness-
of-fit parameter (R2>0.99) and the minimized sum of the squared residuals (Χ2) [21].  
Tail bleeding and rebleeding 
The modified procedure of Gui et al [22] was used for the tail bleeding test.  Two-
month-old FIXKO and wild-type (WT) C57BL/6 mice were selected based on matched 
weight and sex. Infused FIXKO mice were administered with 200 IU/kg r-FIX or 200 
IU/kg tg-FIX five minutes before tail transection.  Mice were anesthetized with 2.5% 
avertin.  The mice were maintained at 37 ºC, and tail transection was performed at 1.5 
mm cross-sectional diameter of the tail.  The tail was then placed in saline and kept at 37 
ºC where it was allowed to bleed until cessation or until 10 minutes had passed.  The time 
of cessation was recorded.  After 10 minutes had passed, 1 minute of pressure was 
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applied to the tip of the tail to cease bleeding.   The clot was stripped after thirty minutes 
had passed since the initial transection.  The tail was then placed in saline and kept at 37 
ºC where it was allowed to bleed for 10 minutes until cessation of bleeding occurred.  
The mice were then allowed to wake up and were observed for 8 hours.   
Statistical analysis and curve fitting 
Pharmacokinetic parameters were calculated for all studies using a model 
independent method [23].  The area under the curve (AUC) and the area under the first 
moment curve (AUMC) with and without extrapolation to infinity were calculated by 
numerical integration of the exponential decay equation that best fitted each data set 
using Mathlab 14.0 (PTC, Needham, MA USA).  Mean residence time (MRT) was 
calculated from these parameters according to Shapiro at al [20].    
All statistical calculations and curve fitting modeling using non-linear regression 
methods were done with GraphPad Prism 5.0 software (GraphPad Software, San Diego 
CA, USA) [21, 24].  Statistical comparison of data sets was done using one-way analysis 
of variance (ANOVA) with Dunnett’s test for multiple comparisons.  A P-value > 0.05 
was considered not significant.  
 
2.4 Results 
Terminal Phase Clearance Study 
All FIXKO mice reported on in this study remained healthy during the assay 
period in both terminal and recovery phase studies. The assays of the antigen 
concentration and activity levels due to infusions of tg-, r-, and pd-FIX can be seen in in 
Figure 2.1.  Activity clearance times remained approximately the same for all three 
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species of FIX; however, antigen clearance times for tg-FIX indicate that the tg-FIX in 
the bloodstream is rapidly cleared.  The regression analyses of all three species indicate 
that the MRT of tg-FIX according to the activity assay is within normal range for a 
hemophilia B treatment into FIXKO mice (Table 2.1).  When applied to the antigen 
assay, the tg-FIX has a third of the MRT of both commercial variants of FIX (Table 2.1).  
The specific activities of the samples demonstrate that while r-FIX and pd-FIX remained 
near 200 IU/mg, the normal activity for FIX, tg-FIX began with very low specific activity 
and rapidly increased to an above normal specific activity level as the antigen levels 
rapidly decreased, displayingP < 0.01 for tg-FIX compared to r-FIX and pd-FIX, and the 
activity levels decreased at a normal pace with no significant difference between 




Figure 2.1. Percent of coagulation activity and antigen levels of FIX in circulation during the 
terminal phase.  FIXKO mice were infused at a calculated target dose concentration of 75 μg FIX/mL 
mouse plasma.   Coagulation activity (A) and FIX antigen levels (B) were fitted using a double exponential 
decay model.  ● pd-FIX (n=8), ■ r-FIX (n=8), and ▲ tg-FIX (n=8).  Data was normalized using the first 
data point at time=30 min as the common denominator. Data represent mean values ±SEM. 
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Figure 2.2. Specific activity of FIX during the terminal phase. FIXKO mice were infused at a calculated 
target dose concentration of 75 μg FIX/mL mouse plasma.   ● pd-FIX (n=9), ■ r-FIX (n=8), and ▲ tg-FIX 
(n=8). Data represent mean values ±SEM. 
 
Table 2.1. Pharmacokinetic variables during the terminal phase.  FIXKO mice were infused at a 
calculated target dose concentration of 75 μg FIX/mL mouse plasma, and pharmacokinetic variables were 
determined based on aPTT and ELISA measurements.
 aPTT 




(h) AUC AUMC R
2 
pd-FIX 258 14.2 9.7 599 3740 0.997 
r-FIX 137 11.2 8.5 578 3550 0.999 
tg-FIX 252 10.8 9.4 514 3310 0.997 
ELISA 




(h) AUC AUMC R
2 
pd-FIX 258 9.7 7.1 483 2400 1 
r-FIX 137 13.8 8.2 487 2450 1 
tg-FIX 252 6.8 2.4 222 468 0.998 
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Recovery Phase Clearance Study 
The recovery phase studies showed distinct pharmacokinetic regimes for each 
FIX variant.  Activity levels and antigen levels decreased the most rapidly in tg-FIX, 
followed by pd-FIX, and r-FIX (Figure 2.3).  The rapid decrease in antigen levels 
witnessed in the terminal tg-FIX study contrasts mildly with the moderate decrease in this 
study.  The specific activities also formed three overlapping regimes for each variant 
(Fig. 4).  These regimes maintained approximately constant specific activity for each 
species for all time points, indicating the rate of clearance according to both antigen and 
activity assays is equivalent.  MRT for all samples decreased to approximately 3 hours 





Figure 2.3. Percent of coagulation activity and antigen levels of FIX in circulation during the 
recovery phase FIXKO mice were infused at a calculated target dose concentration of 35 μg FIX/mL 
mouse plasma.   Coagulation activity (A) and FIX antigen levels (B) were fitted using a double exponential 
decay model.  ● pd-FIX (n=9), ■ r-FIX (n=8), and ▲ tg-FIX (n=8).  Data was normalized using the first 
data point at time=30 min as the common denominator. Data represent mean values ±SEM. 
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Figure 2.4. Specific activity of FIX during the terminal phase. FIXKO mice were infused at a calculated 
target dose concentration of 35 μg FIX/mL mouse plasma.   ● pd-FIX (n=9), ■ r-FIX (n=8), and ▲ tg-FIX 
(n=8). Data represent mean values ±SEM. 
 
Table 2.2. Pharmacokinetic variables during the recovery phase. FIXKO mice were infused at a 
calculated target dose concentration of 35 μg FIX/mL mouse plasma, and pharmacokinetic variables were 
determined based on aPTT and ELISA measurements. 
aPTT 




(h) AMC AUMC R
2 
pd-FIX 205 1.6 2.3 35.3 482 0.999 
r-FIX 282 1.2 1.8 37.4 519 0.999 
tg-FIX 207 0.7 1 31 403 0.989 
ELISA 




(h) AMC AUMC R
2 
pd-FIX 205 2.1 3 36.8 507 0.999 
r-FIX 282 1.7 2.5 34.1 466 0.997 




Tail cut studies confirmed that infusions of tg-FIX and r-FIX are capable of 
restoring hemostasis in FIXKO mice to levels similar to WT mice at both 5 (immediate 
hemostasis) and 30 minutes (secondary bleeding) (Fig. 2.5).  All infused mice and WT 
mice had significantly faster clotting than untreated FIXKO mice while the clotting times 
for infused mice and WT mice were not significantly different.  Rebleeding was seen in 
approximately half of the treated and WT mice, while all but one of the untreated FIXKO 
mice was observed to rebleed (Table 2.3). All treated FIXKO and WT mice survived and 
displayed no sign of distress during the 8 hour observation period in contrast to two of the 
eight mice from the untreated FIXKO group which were euthanized in compliance with 
the animal protocol.   
 
Figure 2.5. Bleeding time after tail transection. Hemostatic effect in vivo of tg-FIX in infused 
hemophilia B knockout mice.  Time from tail transection to bleeding termination (A).  After 10 minutes, 
bleeding was ended by application of firm pressure.  After 30 minutes from time of bleeding termination, 
the clot was removed and secondary bleeding was recorded until bleeding termination (B).  In infused 
mice, 200 IU/kg of either r-FIX or tg-FIX was infused five minutes prior to infusion.  Significant variance 
(P < 0.001) was indicated by WT, r-FIX, and tg-FIX when compared to FIX-/- for both tail cuts [WT (n=8), 
FIX -/- (n=8), r-FIX (n=8), and tg-FIX (n=8)]. 
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Table 2.3. Tail Transection Bleeding and Rebleeding. FIXKO mice were infused with 200 IU/kg r-FIX 
or tg-FIX.  5 minutes after infusion, a tail transection was performed on the infused mice, untreated FIXKO 
mice, and WT mice. Time of bleeding cessation was recorded and if no cessation occurred in 10 minutes 
before, pressure was used to terminate bleeding. 30 minutes after transection, the clots were stripped and 




1st Bleeding Time 
(5 Minutes Post 
Infusion)  
2nd Bleeding Time  
(30 Minutes Post 
Infusion) 
Delayed Rebleeding 
(8 hours post 
transection) 









r-FIX 2.33 1.51 1.41 0.84 3/8 (38%) 
tg-FIX 3.20 3.04 2.17 1.44 4/8 (50%) 
WT 3.60 3.20 1.39 1.18 3/8 (38%) 
FIX-/-(untreated) 8.94 0.92 8.45 1.15 7/8 (88%) 
 
2.5 Discussion 
 The comparative pharmacokinetic studies of pd-FIX, r-FIX, and tg-FIX have 
revealed that tg-FIX demonstrates reduced MRT in both the recovery and terminal phases 
following injection of FIX into FIXKO mice.  However, tail clip studies revealed that tg-
FIX restored hemostasis to FIXKO mice similarly to r-FIX, and the treated FIXKO mice 
had bleeding times nearly identical to WT mice.  Interestingly, FIXKO mice treated with 
tg-FIX in the long-term, higher dose study maintained pharmacokinetic variables nearly 
identical to r-FIX and pd-FIX.  This is in stark contrast to the antigen levels of the mice 
from the same studies which had a significant drop in the pharmacokinetic variables.  
This phenomenon has been observed elsewhere in literature, and is attributed to 
extravascular partitioning of the FIX [25-27].  This extravascular partitioning in previous 
literature was caused by a modification to the Gla domain of FIX.  FIX contains 12 Gla 
residues which can are γ-carboxylated in pd-FIX [15]; however, tg-FIX has been found to 
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have an average of 10-11 γ-carboxylated Gla residues [12] and while r-FIX has been 
previously be characterized to have an 11-12  γ-carboxylated Gla residues with Gla 
residue 11 or 12 being under γ-carboxylated [28].  As r-FIX provides normal 
pharmacokinetics in FIXKO mice, tg-FIX is most likely under γ-carboxylated in a 
different region of the Gla Domain. 
Despite the effect of the changed conformation of tg-FIX on pharmacokinetic 
variables, bleeding times indicated that tg-FIX provided safe and effective treatment to 
FIXKO mice.  WT, r-FIX infused FIXKO, and tg-FIX infused FIXKO mice had 
significantly reduced bleeding times compared to untreated FIXKO mice, while r-FIX 
and tg-FIX infused FIXKO mice regained hemostasis in a range of time that was 
insignificantly different from WT mice.  These results indicate that the dose of tg-FIX 
delivered to these FIXKO mice was sufficient to maintain hemostasis for two bleeding 
events in the recovery phase.   While rebleeding was an issue in mice treated with tg-FIX, 
the occurrence of rebleeding was not significantly different than FIXKO mice treated 
with r-FIX or WT mice. 
These results indicate that tg-FIX has potential use as a pharmacological agent.  
While further studies will need to be performed to establish the pharmacokinetics of 
multiple infusions, the ability of tg-FIX to restore hemostasis to FIXKO mice who have 
been induced with a lethal injury for normal FIXKO mice shows the potential of tg-FIX 
as a treatment option.  In the most conservative case, tg-FIX could be of use for treatment 
of hemophilia B patients undergoing surgery [29, 30], where large doses of FIX are 
traditionally administered to ensure that primary initial clotting occurs and that secondary 
internal bleeding is prevented.  Clinical studies have also shown that continuous infusions 
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of FIX result in higher antigen response levels at lower doses of FIX over time [31], a 
phenomenon attributed to extravascular filling [26].  The antigen clearance times of tg-
FIX, which are similar to the high-extravascular affinity K5A FIX of Gui et al. [27], 
indicate that tg-FIX has increased extravascular sequestration compared to pd- and r-FIX.  
The medical relevance of extravascular partitioning of FIX is still an object of current 
debate, and thus the fate of tg-FIX compared to pd-FIX and r-FIX as a prophylactic agent 
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3.1 Abstract 
Background: Multiple gene transgenesis was used to produce a non-processionally 
carboxylated, biologically active, recombinant human factor IX (tg-FIX) protein from the 
milk of transgenic pigs.  
Objective:  The manipulation of FIX circulation residence time by extravascular 
reservoir filling versus permanent clearance was studied in hemophilic B dogs using 
crossover infusion of tg-FIX and pd-FIX.  
Methods:  Mass spectrometry and metal-dependent monoclonal antibody mapping by 
Biacore were used to characterize the Gla domain of tg-FIX.  The cross-over, IV infusion 
35 
of plasma-derived FIX (pd-FIX) and tg-FIX were administered at 50 IU/kg to hemophilic 
B dogs as follows:  
 Dog O06 was infused with a single dose of active tg-FIX;  
 Dog O25 was infused with pd-FIX and at 48 hours was reinfused with active tg-
FIX;  
 Dog O05 was infused with active tg-FIX and at 48 hours was reinfused with  pd-
FIX;  
 Dog O66 was infused with active tg-FIX and at 72 hours was reinfused with 
whole population tg-FIX.  
For all studies, plasma antigen, one-stage clotting activity, and whole blood clotting times 
(WBCT) were assessed.  Recovery phase half-life and terminal phase mean residence 
time (MRT) were calculated.  
Results: The tg-FIX possesses in vitro coagulation activity comparable to therapeutic 
grade pd-FIX while containing a unique, non-processive γ-carboxylation in positions 7-
10 of the Gla domain. The pharmacokinetics observed during cross-over infusion studies 
between pd-FIX and tg-FIX showed a  strong dependence on the FIX species first 
infused:  the latter infused species presented a >2-fold lengthened recovery phase and 
mean residence time (MRT) from <30 hours to about 40 hours.  The time course 
coagulation activity by WBCT was also lengthened and sustained in excess of 100 hours 
for all tg-FIX/ pd-FIX cross-over infusions, reflecting an increased plasma side 
partitioning relative to extravascular storage. The tg-FIX had rapid plasma concentration 
fall-off for all dogs having no prior exposure to exogenous FIX and thus presented a 
much faster extravascular partitioning kinetics relative to pd-FIX. 
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Conclusion:  These IV infusion studies show that extravascular filling phenomena can be 
used as a vehicle to substantially lengthen circulation residence time for FIX.  
 
3.2 Introduction 
Hemophilia B (HB) is a bleeding disorder characterized by the deficiency of 
biologically active coagulation factor IX (FIX) [1, 2].  Periodic replacement therapy by 
intravenous (IV) infusion is recommended to decrease the occurrence of bleeding 
episodes in most patients.  However, this therapy is complicated by the rapid clearance of 
FIX from circulation [3, 4], the development of inhibitors which can dramatically 
increase the volume of FIX needed for periodic replacement therapy [5], and the 
differences in FIX biotherapuetics which are currently derived from pooled human 
plasma (pd-FIX) and recombinant animal cell culture bioreactors (r-FIX) [6-11].  As a 
result, current FIX bioengineering seeks to lengthen its plasma residence time using 
modifications such as PEGylation [12], the addition of additional glycosylation sites [13], 
albumin fusion [14], and FIX immunoglobulin fusion [15].  In parallel, new recombinant 
production methods are being developed to increase the abundance of FIX by using 
higher animal cell culture density bioreactors [16] and also the milk of transgenic 
livestock [17-19].  Transgenic livestock is viewed as a modern method to overcome 
traditional limitations of cell density in mammalian cell reactors [20], and with the advent 
of new tools for genetic manipulation, a way to create functional posttranslational 
modifications despite rate limitations [21, 22]. 
The above efforts to improve HB therapy would be advanced by a deeper  
understanding of the vascular transport phenomena that determine extravascular storage 
37 
levels of FIX [23, 24].  For example, the molecular engineering that lengthens FIX 
circulation residence times should also avoid an adverse impact on the hemostatic role 
that FIX likely plays while residing in extravascular reservoirs.  Importantly, in the 
context of replacement HB therapy, the hemostatic balance associated with FIX in 
extravascular reservoirs with that of permanent hepatic clearance by the liver is not yet 
known [24, 25]. This important physiology is obscured by the fact that the liver is both 
responsible for permanent clearance of plasma proteins and is a highly vascularized organ 
that can be a major endothelial and extravascular reservoir for FIX [3, 26].  In mouse [3, 
4], rat [27], and baboon studies[26], high levels of radio-labeled FIX accumulated in the 
liver shortly after IV infusion.  While a component of the clearance mechanism of 
glycoproteins like FIX by the liver has been attributed to hepatic asialoglycoprotein 
receptors, a detailed understanding of permanent clearance from plasma has not been 
described  [18].  Moreover, the nature of the occupation of IV infused FIX within the 
liver is not yet known in the context of permanently cleared FIX versus that which is 
hemostatically present in hepatic or other extravascular reservoirs.      
The pharmacokinetic (PK) behavior of pd- and r-FIX in plasmin is well 
characterized in HB dog [8] and humans [28-35].  However, the endothelial and 
extravascular partitioning of FIX is still being characterized.  One attempt to characterize 
this phenomenon was a study in which pd-FIX and r-FIX variants were IV infused into 
the saphenous veins of HB mice [4, 36]. In addition, Gui et al. has established that the 
vitamin K-dependent γ-carboxyglutamic acid (Gla) domain of pd-FIX [37, 38] strongly 
interacted with collagen IV found in the extracellular matrix (ECM) of endothelial cells 
[4, 39].  These studies demonstrated that the collagen binding affinity of FIX could be 
38 
enhanced or decreased by changes in Gla domain conformation or mutations in the Gla 
domain [4, 40].  More recently, HB mice studies by Feng et al. [23] have shown that pd-
FIX can occupy endothelial and extracellular reservoirs for more than seven days while 
being undetected in plasma, and concluding that three-fold more FIX is contained in 
these extravascular reservoirs than in circulation.  Importantly, the above studies in vivo 
showed that differences in Gla domains between pd-FIX and bioengineered r-FIX affect 
the relative balance of extravascular storage and plasma residence time.   
Recently, the evidence of the large amounts of FIX residing in the extravascular 
reservoirs of different organs of normal baboons was further illuminated [12].  This 
recent analysis readdressed the data from Stern et al. [26] that studied bovine FIX infused 
at high levels into a normal baboon. This study reported displacement of endogenous 
baboon FIX into circulation: when high levels of IV bovine FIX were infused, the antigen 
levels of baboon FIX were found to rise to over twice normal levels.  Thus, there exists 
important evidence in a primate model that large amounts of FIX both exist and are 
displaceable from extravascular reservoirs. While no comparable study has been made in 
normal or HB human subjects, those patients who express no plasma FIX antigen need 
more FIX administered to achieve the equivalent plasma antigen levels during the 
recovery PK phase than those who express antigen [23, 24].  These HB patients 
potentially present an antigen structure that still has significant endothelial avidity and the 
ability to load extravascular space, but has defective coagulation activity.   
Collectively, the above data in HB mice, rats and normal baboons led us to infuse 
r-FIX made in the milk of transgenic pigs (tg-FIX) in a crossover study with pd-FIX. This 
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paper details the preclinical administration of tg- and pd-FIX to HB dogs, a standard 
large animal model for hemophilia [41-43].  
 
3.3 Materials and Methods 
Hemophilia B Dogs 
This crossover study between pd-FIX and tg-FIX was conducted on four HB dogs 
at the Francis Owen Blood Research Laboratory at the University of North Carolina at 
Chapel Hill.  All studies were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill.  Exclusion criteria were 
clinically overt illness, abnormal clinical serum chemistry or hematology parameters (i.e. 
complete blood counts and platelet counts), and treatment with FIX in the 3 weeks prior 
[44].   
Materials 
All buffer components were purchased from VWR International LLC (Radnor, 
PA, USA), Thermo Fisher Scientific (Waltham, MA, USA) or Sigma (St. Louis, MO, 
USA) unless otherwise stated.  For these studies, tg-FIX was purified using a modified 
version of the procedure of Lindsay et al. [17].  Size exclusion chromatography (SEC) 
was used to polish the purified sample into inactive, active, and activated populations.  
Whole population tg-FIX contained 20% inactive tg-FIX and 80% active tg-FIX 
population with activity calculated based on one-stage clotting assay and ELISA of the 
tg-FIX before recombining the two fractions.  Freshly immunopurified stocks of pd-FIX 
were provided by Revobiologics, Framingham MA.  The integrity of the purified pd-FIX 
and tg-FIX was verified by SEC and 12% sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis (SDS-PAGE) under non-reduced and reduced conditions and Western 
blot detection using an anti-human FIX rabbit polyclonal (Sigma, St Louis, MO, US) 
paired with a goat anti-rabbit IgG H&L peroxidase conjugate (Sigma, St Louis, MO, US).  
The procoagulant activity of the stock protein solutions was measured with a one-stage 
clotting assay as previously described [17]. The stocks of therapeutic grade r-FIX 
(BeneFIX, Pfizer, USA) were expired for clinical use, but when used in experiments, 
exhibited full procoagulant activity by one-stage clotting assay.  FIX activity was 
measured in international units, with 1 unit corresponding to the activity of FIX in 1 mL 
of plasma which corresponds to a value of 200 IU/mg.  All active FIX species were 
measured with activities between 150-250 IU/mg. 
Affinity Separation of Purified tg-FIX 
A human factor IX affinity column was constructed using a custom Gla domain 
anti-FIX Mg2+-dependent 1G7 monoclonal antibody (mAb) (Green Mountain Antibodies, 
USA) which was bound to Streamline rProtein A (GE Healthcare, USA).  tg-FIX, r-FIX, 
and pd-FIX were dialyzed into an equilibrium buffer containing 20 mM imidazole, 
50mM NaCl, 1.1 mM CaCl2, and 0.6 mM MgCl2 at pH 7.4 in snake-like dialysis 
membranes.  The dialyzed FIX species were loaded onto the 1G7 mAb column and 
equilibrated with two column volumes (CV) of equilibrium buffer and washed with three 
CV of high salt equilibrium buffer containing 500 mM NaCl.  Unbound FIX was 
collected and then concentrated using Amicon Ultra 10 kDa molecular cut-off centrifugal 
filter (Millipore, Billerica, MA, USA).  The loaded 1G7 mAb column was then 
equilibrated with 2 CV of equilibrium buffer and eluted with six CV of 20 mM 
imidazole, 50 mM NaCl, and 5 mM EDTA at pH 7.4.  Bound FIX was collected and then 
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concentrated using Amicon Ultra 10 kDa molecular cut-off centrifugal filter (Millipore, 
Billerica, MA, USA). The chromatography and fraction collection was performed on a 
BioCad Vision chromatography station equipped with an integrated fraction collector 
(Applied Biosystems, Carlsbad, Ca, USA). 
Biacore binding interaction of factor IX to Gla domain monoclonal antibodies.  
A Biacore T100 Series S CM5 chip was coupled with protein A/G (Pierce 
Biotechnology, Rockford IL) in 10mM sodium acetate pH 4.0 using the amine coupling 
procedure with a target of 1000 Response Units (RU) as described by Biacore (Uppsala, 
Sweden). On average we obtained 1015 RU protein A/G covalently bound to the chip. 
For a control surface, the flow cell was activated with EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride) and NHS (N-hydroxysuccinimide) 
and blocked by 1M ethanolamine-HCl pH 8.5.  The Biacore chip, EDC, NHS and 
ethanolamine were all purchased from GE Healthcare (Piscataway, NJ).  100 nM factor 
IX Gla domain Mg2+-dependent mAb, 1G7, in screen buffer (12mg/mL carboxymethyl-
dextran sodium salt, 12mg/mL bovine serum albumin, and HEPES buffered saline with 
0.005% (v/v) P20 pH 7.4) or the Ca2+-dependent mAb, SB 249417, were captured 
separately onto the protein A/G surface. Using a 5 μl/min flow rate and a contact time of 
2 minutes, we obtained on average 3500 RU captured mAb.  On the control surface we 
used screen buffer with no mAb under the same conditions.  After sensogram 
stabilization on both surfaces, varying concentrations of pd-FIX, r-FIX, inactive tg-FIX, 
or active tg-FIX (12.5-200nM) in running buffer (5mM calcium HBS-P pH 7.4) were 
flowed over the control and mAb surfaces at 30 μl/min for 2 minutes. Dissociation of FIX 
was monitored for 5 minutes using running buffer at the same flow rate.  Surfaces were 
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regenerated using 10mM glycine pH 1.5 for half a minute at 30μl/min.  Both surfaces 
were washed with running buffer for 2 minutes before the next run. Analysis was 
performed using the Biacore T100 evaluation software v1.1.1 (Biacore Uppsala, Sweden) 
and sensograms displayed using Microsoft Excel.   
Mass Spectrometry 
Samples of r-FIX and active tg-FIX were activated with factor XIa  (FXIa) 
(Haemtech, Essex Junction, VT) using a 1:100 (w:w) enzyme to substrate ratio in 5mM 
CaCl2, 1X TBS, pH 7.4 at 37°C for 1.0 hour. After activation, the samples were quenched 
with 1.2 moles of EDTA per mole of Calcium and stored at -80oC until further analysis. 
LC-ESI-TOF mass spectrometry (MS) analysis was performed on an Agilent 
1200 capLC system with an Agilent 6210 ESI-TOF MS.  Solvent A was 0.1% formic 
acid (Fluka) (v/v) in deionized water.  Solvent B was 0.1% formic acid (v/v) in 
acetonitrile (Burdick and Jackson).  The column was an Agilent 300SB-C8 Poroshell 
column:  7.5 cm L x 0.5 mm ID, 5 micron particle size.  The samples were diluted in 
Solvent A in the HPLC vial and loaded in the autosampler.  Approximately 35 pmol of 
sample was injected on the column in a 40 microliter injection volume.  The column was 
pre-equilibrated with 5%B; the flow rate was 20 microliters/minute; the column oven was 
set at 37oC; the autosampler was set at 10oC.  After injection, the column was washed for 
5 minutes with 5% B, then a linear gradient up to 20%B over 10 minutes, followed by a 
linear gradient up to 55% B over 70 minutes.  The column was then cleaned by ramping 
up to 95% B for 5 minutes and then a series of three cycles of 10%B to 70% B, and then 
the column was re-equilibrated for >10 CV with 0 %B for the next injection.  A blank 
injection was performed in between each sample to minimize column carryover.  MS data 
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were acquired with MassHunter in positive mode with the following parameters:  4000 V 
source voltage, 325oC nebulizing gas temperature, 7 L/min gas flow rate, internal 
reference mass of 922.01 m/z.  MS data were analyzed using Agilent’s Qualitative 
Analysis (version B.01.03).    
Hemophilia B Dog Studies 
Four different HB dogs were IV infused with 50 IU/kg body weight with either pd-
FIX or tg-FIX as follows: 
 Dog O06 was infused with a single dose of active tg-FIX;  
 Dog O25 was infused with pd-FIX and at 48 hours was reinfused with active tg-
FIX;  
 Dog O05 was infused with active tg-FIX and at 48 hours was reinfused with  pd-
FIX;  
 Dog O66 was infused with active tg-FIX and at 72 hours was reinfused with 
whole population tg-FIX.  
Native and citrated whole blood (for preparing plasma) samples were taken at 15 and 30 
minutes then at 1, 2, 4, 8, 12, 24, 48 hours post FIX infusion.  At 48 hours (O25 and O05) 
and 72 hours (O66), FIX concentrations had returned to near baseline levels for all dogs.   
The same time points were taken after the second infusion and additional sampling was 
done twice daily until ~360 hours post infusion.  PK parameters were calculated for both 
studies using a model independent method [45].  Mean residence time (MRT) was 
calculated from these parameters according to Shapiro et al. [46].    
Pharmacokinetic Assays 
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Human FIX antigen concentration, activity, and whole blood clotting time 
(WBCT) were assayed for all plasma samples collected.  FIX antigen plasma 
concentration was evaluated by a FIX-ELISA kit (Kordia), and FIX activity level was 
evaluated using a one-stage clotting assay based on the Behring Coagulation Timer 
(Siemens Healthcare, Diagnostics Products GmbH, Marburg, Germany) [47].  Procedures 
for both the  one-stage clotting assay and ELISA have been described previously in Nolte 
et al. [47].  WBCT was assayed as previously described using the ‘two-tube’ method 
using silicone-coated tubes which were tilted every 30 seconds.  [44, 48, 49]. 
 
3.4 Results 
γ-Carboxylation of the Gla domain 
 Previous analysis of pd-FIX showed that normal human donors produce 
exclusively 12 Gla pd-FIX under normal conditions [50]. However, both r-FIX and tg-
FIX samples contain more varied under-carboxylated Gla populations. Previous amino 
acid analysis of FIX after basic hydrolysis has stated that pd-FIX contains on average 
10.5 mol Gla/mol pd-FIX, r-FIX contains on average 6.5 moles Gla/mol r-FIX, and tg-
FIX contains on average 6.0 mol Gla/mol tg-FIX [17].  The MS structural 
characterization of the r-FIX revealed the presence of a mixed population of 10, 11, and 
12 Gla r-FIX (Fig. 3.1A).  12 Gla r-FIX was the predominant species for the sample, 
containing an estimated ~67% of the sample, followed by ~31% of 11 Gla r-FIX, and 
~2% 10 Gla r-FIX.  For active tg-FIX, 9, 10, 11, and 12 Gla species are present at an 
estimated ~9%, ~47%, ~28%, and ~16% of the sample respectively (Fig. 3.1D), all of 
which contain γ-carboxylated 1-6 Gla domains according to MS and SB 249417-
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conjugated Biacore (Table 3.1). Each FIX Gla species contains two peaks due to ±beta-
hydroxylation. 
 
Figure 3.1. LC-ESI-TOF mass spectrometry analysis of FIX gla content. (A, B, C) r-FIX and (D, E, F) 
tg-FIX were analyzed using 1G7 mAb affinity column. (r-FIX: A; tg-FIX: D) Active FIX was loaded onto 
the 1G7 affinity column where the (r-FIX: B; tg-FIX: E) unbound FIX and (r-FIX: C; tg-FIX: E) eluted 
bound FIX were collected.  Samples were treated with factor XIa to activate the FIX and analyzed with LC-
ESI-TOF mass spectrometry. 
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Table 3.1. Characteristics of pd-FIX, r-FIX, and tg-FIX 
 
  
 1G7 mAb column purification of pd-FIX, r-FIX, and tg-FIX resulted in starkly 
different chromatography profiles.  The 1G7 column was capable of binding 100% of the 
pd-FIX; however, for r-FIX and tg-FIX, 30-50% of the FIX remained unbound to the 
column and was removed by the salt wash.  MS revealed that the purification of the r-FIX 
Characteristic pd-FIX [11] r-FIX [11] tg-FIX 
Primary structure Ala148/Thr148 Ala148 Thr148 
Specific Activity (IU/mg) 200 150-200 150-250 
Total γ-carboxyglutamic acid 
content 
  12 of 12 Gla 
  11 of 12 Gla 
  10 of 12 Gla 















Biacore: Steady-State KD (nM) 
 Ca2+-dependent mAb 





































β-hydroxyaspartic acid (Asp 64) 37% 46% 40-50% 
Pro-peptide content None detected None detected None detected 
Activated FIX 0.21% ±0.010% 0.11% ±0.0019% None detected 
Tyr 155 sulfation >90% <15% 10-15% 
Ser 158 phosphorylation[18, 51] >90% <1% 70% 
Sialylation (nmol/mol FIX)[18, 51] 8.8 6.5 4-5.5 
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by 1G7 mAb column successfully removed over 70% of the FIX species with less than 
12 Gla (Fig. 3.1B and 3.1C).  In contrast, 1G7 mAb purification of tg-FIX showed 
retention of 10, 11, and 12 Gla species in the eluate while also containing unbound 
populations of 9, 10, 11, and 12 Gla species in the salt wash (Fig. 3.1E and 3.1F).  The 
differences in the binding of the under-carboxylated species of r-FIX and tg-FIX to 1G7 
mAb indicate that the order of γ-carboxylation in each FIX species is different.  The MS 
analysis indicates from the diversity of under-carboxylated species in the tg-FIX that the 
11-12 Gla domain detected by 1G7 is γ-carboxylated more consistently than r-FIX; 
however, tg-FIX is more consistently missing at least one Gla domain in the 7-10 Gla 
residue range according to both Biacore and MS.  These differences in the Gla domain 
conformation between species is likely to exhibit stark differences in extravascular 
binding [4, 39].   
Pharmacokinetics of single-dose of active tg-FIX (O06) 
 When tg-FIX was infused into HB dog without a transfusion in the previous three 
weeks (Fig. 3.2), quantitative pharmacokinetic variables were unobtainable at an 
acceptable degree of certainty.  Qualitatively, both the antigen concentration and activity 
levels exhibited a rapid decrease in FIX presence.  The 50 IU/kg dose of tg-FIX resulted 
in an immediate response corresponding to a concentration 12% of normal and an activity 
level 15% of normal.  However, FIX antigen concentration and activity levels were 
undetectable by 8 and 24 hours respectively.  Comparatively, this single infusion of tg-
FIX corresponded to the pharmacokinetic behavior of a FIX K5R mutant produced by 




Figure 3.2. Effect of tg-FIX on plasma activity and antigen levels in hemophilia B dog.   FIX activity 
measured by (A) antigen measured by ELISA and (B) one stage clotting assay.  Each line represents an 
individual trial of 50 U/kg tg-FIX administered to a hemophilia B dog. 
 
Pharmacokinetics of crossover-dosing of pd-FIX followed by active tg-FIX (O25) The 
initial dosing of 50 IU/kg of pd-FIX responded within the normal pharmacokinetic range 
for FIX replacement therapy (Table 3.2 and 3.3). Peak antigen concentration and activity 
levels were 80% and 68% of normal respectively, and by 48 hours the majority of the pd-
FIX had been cleared from the plasma, with antigen and activity levels between 10-11% 
of normal (Fig. 3.3).  The infusion of tg-FIX at 48 hours post pd-FIX infusion also 
produced elevated antigen concentration and activity levels (Table 3.2 and 3.3).  The 
MRT of the tg-FIX surprisingly surpassed the initial infusion of pd-FIX for this trial, 
although the tg-FIX only reached peak antigen and activity levels of 70% and 36% of 
normal respectively.  The tg-FIX activity level and antigen concentration remained 
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detectable for over 72 hours post infusion, sharply contrasting the rapid decrease in these 
parameters seen in the single infusion trial (Fig. 3.2 and 3.3). 
 
Figure 3.3. The crossover pharmacokinetics of IV injected pd- and tg-FIX in Hemophilia B dog.  (A, 
B) 50 U/kg of pd-FIX was initially IV delivered to a hemophilia B dog (O25), followed by 50 U/kg of tg-
FIX delivered 48 hours after initial delivery of pd-FIX. (C, D) 50 U/kg of tg-FIX was initially IV delivered 
to a hemophilia  B dog (O25), followed by 50 U/kg of pd-FIX then delivered 48 hours after initial delivery 
of  pd-FIX.  Antigen concentration and activity levels were determined by (A, C) ELISA and (B, D) one 
stage clotting assay respectively. 
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Table 3.2. Pharmacokinetic properties of pd- and tg-FIX crossover studies as measured by ELISA.   








AUC AUMC R2 
pd-FIX (O25) 1.9 24 31 1200 14000 .994 
pd-FIX post 
tg-FIX (O05) 
1.9 30 40 450 8200 .994 
tg-FIX (O05) 0.5 4.3 5.5 46 240 .999 
tg-FIX post 
pd-FIX (O25) 
4.9 34 39 1300 41000 .998 
 
 
Table 3.3. Pharmacokinetic properties of pd- and tg-FIX crossover studies as measured by aPTT. 








AUC AUMC R2 
pd-FIX (O25) 3.1 22 28 1400 16000 .993 
pd-FIX post 
tg-FIX (O05) 
1.1 30 42 650 8300 .996 
tg-FIX (O05) 0.4 4.9 6.8 86 550 .983 
tg-FIX post 
pd-FIX (O25) 
2.7 29 38 1900 64000 .995 
 
Pharmacokinetics of crossover-dosing of active tg-FIX followed by pd-FIX (O05) 
 Initial dosing of tg-FIX responded similarly to Dog 066 as expected; however, a 
slightly longer detectable plasma residence time allowed for quantification of the 
pharmacokinetic variables (Tables 3.2 and 3.3).  The MRT of the tg-FIX infused into dog 
O05 based on both activity and antigen assays was less than 18% of the tg-FIX infused 
into dog O25, with the change in procedure being the prior infusion of pd-FIX in dog 
O25 (Fig. 3.2 and 3.3).  FIX composition of the tg-FIX samples delivered to both animals 
51 
was confirmed by one-stage clotting assay, SDS-PAGE, and SEC to be functionally 
identical.  In dog O05, the pd-FIX sample administered 48 post tg-FIX infusion exhibited 
a lower peak response; however, it also exhibited an MRT increased by 29% based on 
antigen levels and 50% based on activity levels (Fig. 3.3).  
Pharmacokinetics of crossover-dosing of active tg-FIX followed by whole population tg-
FIX (O66) 
 Both tg-FIX infusions in the crossover-study were cleared from the plasma at 
rates too rapid for quantification (Fig. 3.2).  Interestingly, activity levels and antigen 
concentration both showed clearance times for both active tg-FIX contained in the first 
infusion of tg-FIX into dog O66 and whole population tg-FIX that remained identical 
despite the 20% increase in concentration of total FIX in whole population tg-FIX from 
active tg-FIX. 
Whole Blood Clotting Times 
 In stark contrast with the low pharmacokinetic variables obtained by one-stage 
clotting assay and ELISA for tg-FIX, all treatments maintained WBCT of less than 20 
minutes for at least 48 hours (Fig. 3.4). Interestingly, all treatments with a prior infusion 
maintained WBCT of less than 20 minutes for at least 72 hours and remained under 60 
minutes for over 100 hours.  Steady-state values were maintained for the longest time 
period in the crossover-dosing of pd-FIX followed by active tg-FIX (O25).  
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Figure 3.4. Effect of tg- and pd-FIX on the WBCT in hemophilia B dog. Time course plotted from 
infusion time until (A) 400 hours and (B) 50 hours.  Circles indicate dogs with no prior infusion in the 
preceding 3 weeks, and squares indicate an infusion of a FIX species given 48 hours before administration. 
 
Safety 
Throughout the study, all animals remained in healthy conditions and showed no 
sign of fever or systemic reaction to the infused materials.  
 
3.5 Discussion 
 These preclinical studies were performed in order to test the safety and efficacy of 
tg-FIX produced in the milk of swine.  In these studies, the tg-FIX was characterized to 
have two vastly different pharmacokinetic profiles based on the prior infused species.  
Based on the similarity of this data to previous research on designed FIX mutants [4, 26, 
39], we believe that these changes in pharmacokinetic are due changes in the Gla domain 
of the tg-FIX and in the filling of the extravascular reservoir. 
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 While the specific activity by one-stage clotting assay is similar for pd-FIX, r-FIX 
and tg-FIX, it is important to note that the Gla conformation of the tg-FIX versus the pd-
FIX and r-FIX is different due to the differences in Gla domain γ-carboxylation [17, 27, 
52]. All major populations of pd-FIX, r-FIX, and tg-FIX were confirmed to contain γ-
carboxylated 1-6 Gla domains by both MS and SB 249417-conjugated Biacore. MS has 
revealed that the tg-FIX has an average carboxylation content 10-11 Gla residues as 
opposed to the 12 fully γ-carboxylated Gla residues found in pd-FIX. When pd-FIX, r-
FIX, and tg-FIX were purified using a column designed with a mAb that targets a 
magnesium dependent, tg-FIX was shown to contain different sub-populations of under-
carboxylated FIX than r-FIX.  Previous literature has stated  that r-FIX [53], when under-
carboxylated, typically does not contain Gla 11 or 12 and this under-carboxylation does 
not affect the function of the r-FIX.  Combined with the exclusive affinity of the 1G7 
mAb to 12 Gla r-FIX compared to other subpopulations of r-FIX, previous literature on r-
FIX and our current data indicate that 1G7 mAb targets either the 11 or 12 Gla site of 
FIX.  The diversity of tg-FIX that bound to the 1G7 mAb indicates that Gla 11 and 12 are 
present in most subpopulations of tg-FIX and that under-carboxylation in tg-FIX occurs 
at Gla 7-10.  As a result, it can be stated that tg-FIX is produced using non-processive 
carboxylation [53-55].  This non-processive under-carboxylation can directly impact the 
tertiary structure of the Gla domain, which is responsible for the binding of FIX to the 
endothelium [4, 39, 40, 56]. 
 These changes in the Gla domain of tg-FIX can be seen in its high avidity for 
endothelium and extravascular reservoirs as evidenced by its rapid plasma falloff when 
exposed to HB dog vasculature which had no prior exposure to FIX.  This avidity is also 
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demonstrated when whole population tg-FIX is administered 72 hours after a tg-FIX 
infusion.  Despite the whole population tg-FIX containing 20% more total FIX, the 
clearance time of the active tg-FIX remained unchanged.  This likely indicates two 
separate mechanisms for the removal of FIX from plasma: the storage of active FIX in 
the extravascular reservoirs and hepatic clearance of inactive FIX. 
 The storage of both tg- and pd-FIX in the extravascular reservoirs can be seen 
in dog studies O25 and O05.  The filling of the vascular space by first species infused in 
three weeks can be seen in the dramatically increased pharmacokinetic properties of the 
second infusion compared to an infusion with no prior infusion in the last three weeks. 
Quantitatively, over a 7-fold increase in residence time can be seen in the tg-FIX that was 
presented with a prior infusion of pd-FIX 48 hours prior earlier, and a 30% increase for 
pd-FIX when presented with a prior infusion of tg-FIX 48 hours earlier. 
Most importantly, WBCT indicate that tg-FIX is capable of providing acceptable 
hemostasis for over 48 hours despite the presences of antigen or activity in the plasma.  
All HB dogs studied remained in healthy condition during the study, indicating that tg-
FIX is both safe and efficacious in HB dogs.  These HB dog studies strongly supports the 
impact of extravascular binding described in molecular and PK terms by Gailani [39] and 
Feng et al. [23]. It further explains the reduced amount of FIX needed over time in 
patients who receive continuous infusions of FIX [24].  We did not document the 
occupation of the extravascular compartment by the FIX species so a direct correlation 
with the PK behavior cannot be performed. However, our results are consistent with the 
effects of the extravascular space loading and its influence on subsequent infusions of 
FIX [4, 26].  Importantly, this effect continued even after plasma levels of FIX antigen 
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and activity have reached a near non-detectable level.  This information provides the 
continued impetus to further detail the potentially profound impact that reservoir 
phenomena have on the general dosing strategy for treating HB and especially in the 
context of design strategies used to achieve longer lasting FIX biotherapuetics. 
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4.1 Abstract 
Deliveries of human factor IX (FIX) to the mucosal lining of the mouth (buccal) 
or gut (oral) are non-intravenous administration methods with inherently low 
bioavailability. The aim of this probative study was to investigate the potential of oral 
and buccal delivery of plasma-derived (pd-) and transgenic milk derived (tg-) FIX in 
mice and dogs.  To survey oral versus buccal delivery, raw milk containing tg-FIX and 
calcium phosphate (CaP) formulated FIX was administered to study animals.  ELISA and 
one stage coagulation assays were used to determine FIX bioavailability.  FIX 
coagulation activity levels of CRM- hemophilic mice increased to 2.7%-4.6%  1 hour 
after feeding 2000 IU/kg raw milk containing tg-FIX, indicating a bioavailability of  
<0.2%.  Furthermore, in 1 of 2 normal dogs the level of FIX antigen and coagulation 
activity increased >13% after 1 hours post-feeding of 250 IU/kg of tg-FIX milk, 
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indicating a minimum of 2% bioavailability.  The CaP microparticles were used to 
buccally deliver pd-FIX, which resulted in a >150 ng/mL FIX antigen level rise in 3 of 4 
normal mice.  In CRM+ hemophilic mice fed CaP:tg-FIX, antigen levels rose >400 
ng/mL after 15 minutes and remained >300 ng/mL for 24 hours. The bioavailability of 
CaP formulations in both CRM- and CRM+ mice was <0.2%. Evidence of the 
displacement of bioengineered FIX from the endothelial reservoirs of CRM+ mice was 
observed after the buccal administration of CaP:tg-FIX.  This work justifies further 
studies in hemophilic dog models through the oral delivery of tg-FIX by lipophilic carrier 
to the normal dog model. 
 
4.2 Introduction 
Hemophilia B [1-5] is currently treated using prophylactic treatment of either 
plasma-derived (pd-) [6, 7] or recombinant FIX [6-8] delivered intravenously (IV) [5, 9-
11].  However, the routine treatment of children frequently requires administration by 
central-venous catheter, which has the risk of complication, including deep-vein 
thrombosis and infection [12, 13]. In addition, the risk of inhibitor development increases 
with each successive FIX infusion during the course of IV therapy [14-16].  
Recent studies on the accumulation of FIX in endothelial reservoirs of hemophilia 
B mice have provided new insight into the pharmacokinetic behavior that occurs after IV 
administration of FIX [3, 17-20].  These studies have shown that point mutations in the 
Gla domain alter the partitioning of FIX into the endothelial reservoirs and, therefore 
alter its pharmacokinetic behavior in circulation, revealing the central role of the Gla 
domain in the reservoir phenomena.  
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A formidable barrier to the development of non IV delivery of hemophilia factors 
is the combination of low bioavailability and the correspondingly inadequate production 
methods for FIX and FVIII.  However,  the oral delivery of 800 units in a single dose of 
liposome encapsulated pd-FVIII into a single hemophilia A patient was previously 
demonstrated to raise FVIII plasma activity levels to 5-10% of normal within 2 hours 
after ingestion [21], and 5% after about 25 hours, establishing a bioavailability of 20%.  
Few studies have reported patient-friendly methods such as buccal administration for 
mouth absorption and oral delivery for gastrointestinal absorption due to the large 
amounts of factor needed for development of these methods. 
The use of transgenic production methods in the milk of livestock or in plants can 
potentially produce >100-fold more recombinant factor than is possible by current large-
scale manufacturing methods [22-25].  For example, FIX antigen that does not have 
coagulation activity has been made in large amounts by transgenic plants  and used to 
reduce the formation of  inhibitors by oral delivery in hemophilic B mice despite low 
bioavailability [14, 26] .  Furthermore, biologically active  FIX has been successfully 
purified from the milk of transgenic (tg-) swine [23].  This probative study reports on the 
administration of active tg-FIX in oral and buccal delivery into normal mice and dogs as 
well as hemophilia B mice.   
 
4.3 Materials and Methods 
All buffer components were purchased from VWR International LLC (Radnor, 
PA, USA), Thermo Fisher scientific (Waltham, MA, USA) or Sigma (St. Louis, MO, 
USA) unless otherwise stated. Transgenic pig milk was collected as previously described 
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[23]. In order to minimize degradation, purification processes were performed at 4?C. 
The stocks of pd-FIX (Mononine®, CSL Behring, USA) were expired for clinical use; 
however, when used in experiments, exhibited full procoagulant activity.  Blood samples 
were assayed for absorption of FIX into blood circulation by h-FIX-ELISA [27] and 
single stage coagulation assay [28]. 
Oral delivery of raw tg-FIX milk to mice  
CRM- FIX knock-out (FIXKO) hemophilic B mice were fed 0.5 mL raw tg-FIX 
milk containing 100 IU FIX/mL after a meal (postprandial) (n=4).  Post-administration, 
plasma samples were collected one hour after dosing. 
Oral delivery of raw tg-FIX milk to dogs 
The study was conducted on one haemostatically normal dog at ProGenetics LLC.  
The protocol was approved by the Institutional Animal Care and Use Committee of 
ProGenetics.  Exclusion criteria were clinically overt illness, abnormal clinical serum 
chemistry or hematology parameters, prior treatment with FIX, and any medical 
treatment, including plasma transfusion, fewer than 14 days prior to inclusion.  The 
normal dog was fed raw tg-FIX milk that provided 250 IU FIX/kg.  Post-administration, 
plasma samples were collected at 1, 2 and 10 hours. 
Purification of tg-FIX 
Whole tg-FIX milk was purified using a modified version of the procedure of 
Lindsay et al. [23].  The modified procedure included centrifugation, affinity 
chromatography, and size-exclusion chromatography.  Affinity chromatography was 
carried out using a Heparin Sepharose 6 Fast Flow (GE Healthcare, Uppsala, Sweden) 
column and a Macro Prep Ceramic Hydroxyapatite Type II – 40 µm (Bio Rad - Hercules, 
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CA, USA), column while size-exclusion chromatography was carried out on a  TSK gel 
G3000SWxl (Tosoh Bioscience, King of Prussia, PA, USA) column.  
Analysis of purified FIX 
The integrity of the purified tg-FIX was verified by standard 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reduced and reduced 
conditions; and Western blot detection using an anti-human factor IX rabbit polyclonal 
(Sigma, St Louis, MO, US) paired with a goat anti-rabbit IgG H&L peroxidase conjugate 
(Sigma, St Louis, MO, US).  The procoagulant activity of the stock protein solutions was 
measured with a single stage coagulation  assay as previously described [23]. 
Formulation of Calcium phosphate (CaP) encapsulated FIX 
CaP particles containing FIX as the active drug were synthesized by co-
precipitation of FIX with the inorganic salt solutions of calcium and phosphate at 4°C 
based on protocols of He et al. [29]. 
Determination of tg-FIX binding efficiency 
FIX binding efficiency to CAP was estimated by the Bradford’s method using a 
Bio-Rad protein assay kit. In most cases, >75% binding efficiency was obtained.  While 
in suspension, these formulations contained 190 to 200 IU FIX/mL which were adjusted 
to 150 IU/mL.   
Determination of particle size.  
Particle size was determined using a Beckman Coulter N4 Plus submicron particle 
sizing machine. Distilled water was used as the diluent. Particle size was analyzed at two 
different angles (60 and 90 degrees). 
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Buccal delivery of CaP:pd-FIX 
CaP:pd-FIX particle suspension containing 191 IU FIX/mL with 1800 nm average 
particle size was administered buccally to  normal CD-1 mice, delivering a total of 49 IU. 
At 1, 2, 4, 6, 24, 48, and 72 hours post-treatment, blood samples were collected. 
Buccal delivery of CaP:tg-FIX  
CaP microparticles were sprayed into the mouths of CRM-FIXKO (n=5) mice 
[30] and CaP:tg-FIX was fed to CRM+ R333Q-hFIX mice (n=7) via the buccal route. 
Post-administration, plasma samples were collected at 15 min, 2hr, and 24hr. 
Dose response of CRM+ R333Q –hFIX mice to buccal delivery of CaP:tg-FIX 
The CaP:tg-FIX was fed at 0, 2000, and 6000 IU/kg to R333Q mice (n=8).  Post-
administration, plasma samples were collected at 15 min, 2hr, and 24hr and the 
absorption of FIX into blood circulation was determined by ELISA using FIX-T148 
antibodies (Green Mountain Antibodies) and Anti-human factor IX (Haematologic 
Technologies Inc.). 
Tail bleeding and rebleeding 
The modified procedure of Gui et al. [3] was used for the tail bleeding test.  Two-
month-old R333Q mice were selected based on matched weight and sex. R333Q mice 
were administered CaP, 2000 IU/kg CaP:tg-FIX, or 6000 IU/kg CaP:tg-FIX 24 hours 
before tail transection.  Mice were anesthetized with 2.5% avertin.  The tail transection 
was performed at 1.5 mm cross-sectional diameter of the tail.  The tail was then placed in 
saline and kept at 37 ºC where it was allowed to bleed until cessation or until 10 minutes 
had passed.  The time of cessation was recorded.  After 10 minutes had passed, 1 minute 
of pressure was applied to the tip of the tail to cease bleeding.   The clot was stripped 
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after thirty minutes had passed since the initial transection.  The tail was then placed in 
saline and kept at 37 ºC where it was allowed to bleed for 10 minutes until cessation of 
bleeding occurred.  The mice were then allowed to wake up and were observed for 8 
hours.   
Statistical analysis 
All statistical calculations were done with GraphPad Prism 5.0 software 
(GraphPad Software, San Diego CA, USA) [31].  Statistical comparison of data sets was 
done using one-way analysis of variance (ANOVA) with Dunnett’s test for multiple 
comparisons.  A P-value > 0.05 was considered not significant.  
 
4.4 Results 
Oral delivery of raw milk containing tg-FIX to mice and dogs 
We chose CRM- hemophilic mice for oral delivery studies due to the absence of 
baseline FIX antigen and activity detected in these animals.   One hour after a single 
feeding of 0.5 mL of raw tg-FIX milk, significant amounts of both plasma-borne antigen 
and active FIX were observed in three of four mice (Table 4.1).   The average plasma 
antigen level detected in these mice at 1 hour post-administration was 5.5 μg/mL, which 
corresponds to 13.8 μg of circulating FIX antigen (Table 4.2).   This circulating antigen 
estimate is equivalent to 1.1% of the total tg-FIX antigen fed in the raw milk.  The level 
of plasma coagulation activity detected in these mice at 1 hour post-administration 
corresponds to 0.04 IU/mL and a minimum bioavailability of 0.2 % of the tg-FIX activity 
from raw milk (Table 4.3).   At this level, the ratio of activity to antigen rise is estimated 
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to be 6.9 IU/mg tg-FIX, which is about 25 to 30-fold lower than the specific activity of 
the most native and biologically active species that was purified from the milk.   










Effective concentration of functional 
transgenic factor IX (μg/mL plasma) 
1 2.3 73.6 2.7% 0.14 
2 7.8 68.4 4.2% 0.21 
3 6.4 67.3 4.6% 0.23 
4 ND‡ - - - 
*Determined by ELISA 
†100% FIX activity is set to be equivalent to 1 IU/mL. 
‡Not detected. 
 
Table 4.2. Estimated plasma levels of FIX antigen and coagulation activity.   Total FIX levels  
based on 10% plasma volume in 25 g mice and 20 kg normal dog. 
  Total FIX Administered 
















Oral Delivery of Milk             
CRM- Mice fed raw 
tg-FIX milk 50 1250 0.04 5.5 0.1 13.8 
Normal dog fed raw 
tg-FIX milk* 5100 40000 0.19 0.9 124 588 
Buccal Delivery of 
CaP:FIX             
Normal Mice fed 
CaP:pd-FIX 49 245 ND† 0.15 ND† 0.4 
CRM+ Mice fed 2000 
U/kg CaP:tg-FIX 40 200 ND† 0.48 ND† 1.2 
*Median change over 10 hours 





Table 4.3. Bioavailability of FIX after oral delivery of raw tg-FIX milk and buccal delivery of 
CaP:pd-FIX and CaP:tg-FIX. 






Ratio of delivered 
activity to antigen 
delivered rise in 
plasma (IU/mg) 
Oral Delivery of Milk       
2000 U/kg CRM- Mice 0.2 1.1 6.9 
250 U/kg Dog 2.4 1.5 210 
Buccal Delivery of Cap:FIX       
2000 U/kg Mice (pd-FIX) ND* 0.2   
2000 U/kg CRM+ Mice (tg-FIX) ND* 0.6   
*Not Detected.  Limit of detection of assay: 0.01 IU/mL 
 
To further investigate the potential of oral delivery of tg-FIX into a more 
preclinically relevant animal model, we fed raw tg-FIX pig milk to two normal adult dogs 
at 250 IU/kg body weight.  Similarly to the CRM- mice, both antigen and activity levels 
were found to rise 1 hour after feeding the tg-FIX milk in one of the two dogs (Fig. 4.1).  
In the responding dog, a rise in plasma FIX antigen (Fig. 4.1A) of 13% and a coagulation 
activity (Fig. 4.1B) of 33% was observed one hour after feeding.  A relatively steady 
level of 13% to 18% antigen and 15 % coagulation activity above baseline was observed 
from 1 to 10 hours post milk administration by feeding. 
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Figure 4.1. FIX levels after oral delivery of raw tg-FIX milk into normal dog.   The animal was treated 
with 250 IU FIX/kg. (A) FIX plasma level determined by ELISA (B) FIX plasma activity determined by 
one stage coagulation assay and error bars indicate the range of for the assay for their respective sample. 
 
CaP formulation for buccal delivery 
We endeavored to administer FIX using a formulation and method of delivery that 
was more defined than feeding raw tg-FIX milk.  CaP precipitation of FIX and its spray 
delivery was chosen to coat the interior surfaces of the mouth of the mice [29, 32].  Both 
pd-FIX and tg-FIX preparations were precipitated by CaP, which resulted in the 




Figure 4.2. CaP:pd-FIX particles used in buccal administration to normal male CD-1 mice. CaP:pd-
FIX was imaged by scanning electron microscope. 
 
FIX plasma levels after buccal administration of CaP:pd-FIX and CaP:tg-FIX 
We probed the buccal delivery efficiency of the CaP formulations of pd-FIX and 
purified tg-FIX using both normal and hemophilic CRM+ mice.  The use of CRM+ 
enabled indirect detection of endothelial reservoir delivery which might occur during 
buccal delivery. The antigen levels in 3 of 4 normal CD-1 mice that were buccally 
administered CaP:pd-FIX at 2000 IU/kg gave an average maximal rise above baseline of 
250 ng/mL ( Fig. 4.3). The average baseline antigen levels ranged from 15 to 25 ng/mL.  
The maximum levels of FIX antigen occurred at 4 to 6 hours post-administration and 




Figure 4.3. FIX plasma levels after buccal delivery of CaP:pd-FIX into CD-1 normal mice. FIX 
plasma levels after buccal delivery of CaP:pd-FIX into CD-1 normal mice.  The animal was treated with 49 
IU of FIX (n=4).   ( ) Mouse 1 ( ) Mouse 2 ( ) Mouse 4.  
When CaP:tg-FIX was administered at 2000 IU FIX/kg to CRM+ hemophilic 
mice (n=7), an increase in antigen level was observed in all mice  (Fig. 4.4).   These mice 
reached a maximum change in FIX antigen level of >400 ng/mL in 15 minutes and 
maintained a FIX antigen level of >300 ng/mL for ten hours.  In contrast, CRM- 
hemophilic mice fed CaP alone (Fig. 4.5A) showed a decrease in FIX antigen.  The 
CaP:tg-FIX administration of 2000 IU/kg was also repeated in a new set of CRM+ mice 
alongside a 6000 IU/kg administration.  CaP delivery to CRM+ mice was used as a 




Figure 4.4. FIX plasma levels after buccal delivery of CaP:tg-FIX into KI-CRM+ R333Q (n=7) and 
CaP into CRM- mice (n=5). Each R333Q animal was treated with 2000 IU FIX/kg.   Both plots were 
determined by ELISA.  (A) FIX levels in plasma (B) Net change in FIX levels in plasma. ( ) FIXKO ( ) 
R333Q (*) P<0.05 (**) P<0.01 (***) P<0.001 (****) P<.0001. 
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Figure 4.5. FIX levels after buccal delivery of CaP:tg-FIX into KI-CRM+ R333Q mice (n=8).  
Activity determined by ELISA.   ( ) 2000 U/kg ( ) 6000 U/kg ( ) Placebo. (*) P<0.05 (**) P<0.01 (ns) not 
significant. 
 
 We used the CRM+ mice to detect displacement phenomena of the inactive 
R333Q FIX from endogenous endothelial reservoirs that might be caused by buccal 
delivery of tg-FIX. Importantly, these ELISA measurements were used specifically to 
detect the threonine 148 natural variant present in the tg-FIX, but not in the R333Q 
inactive variant present in the CRM+ mice.  These tg-FIX specific measurements showed 
no signal in any of treatment groups of CRM+ mice while nonspecific antibody indicated 
elevated levels. 
The tail transection performed at 24 hours after feeding also detected no activity, 
potentially due to endothelial reservoir loading by the tg-FIX .  During the first tail cut a 
significant reduction in bleeding time was observed in mice given 6000 IU/kg (Fig 6A).  
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Twenty minutes after the cessation of bleeding from the first tail-cut, the second tail 
transection was performed.  The second-tail cut produced no significant reduction in 
bleeding (Fig 6B). 
 
Figure 4.6. Bleeding Time after Tail Transection. Hemostatic effect in vivo of tg-FIX in infused R333Q 
CRM+ mice (n=8). Bleeding time caused by tail transection until bleeding termination.  (A) Time from tail 
transection to bleeding termination.  After 10 minutes, bleeding was ended by application of firm pressure.  
(B) After 30 minutes from time of bleeding termination, the clot was removed and secondary bleeding was 
recorded until bleeding termination. (ns) not significant.   
 
4.5 Discussion 
We previously reported the production of >100 IU/mL of tg-FIX activity in the 
milk of transgenic pigs [22, 23]. The antigen content of the pooled milk collected over a 
40 day lactation was reliably detected at 1-1.5 g/l while the coagulation activity varied 
from 40-300 IU/mL, which is 40-300 fold higher activity than is found in human plasma.  
The tg-FIX in the milk was estimated to be about 10-15% biologically active and the 
average specific activity was about 40 IU/mg tg-FIX for all species in the milk.  The most 
biologically active and highly purified tg-FIX preparations were similar in specific 
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activity to pd-FIX at >200 IU/mg [22, 23]. The variability of the activity in raw milk is 
due in part to the proteolytic nature of milk and due to broad distribution of tg-FIX with 
different post-translational modification.  This is especially important with respect to 
sufficient levels of gamma-carboxylation of glutamic acid contained in the Gla domain 
which is required for coagulation activity. Importantly, pig milk is a lipophilic, micellular 
mixture containing 6-8% fat membrane globules that could facilitate oral delivery [21, 
33] and that both mice and dogs readily ingested.   Thus, the raw milk was used both as 
an abundant source and delivery vehicle of FIX activity for probing the possibility of the 
oral delivery of FIX.   
We have used several different animal models to assess the potential for the 
delivery of tg-FIX by oral and buccal administration.   Buccal delivery was explored due 
to the potential for decreased transport limitations that might be present in the mucosal 
tissue of the mouth and also due to its less proteolytic environment relative to the gut.  
However, the decision to predominately use mice despite the more keratinized and likely 
limiting nature of the mouse mouth relative to that of dogs [32] was due to low body 
weight and access to statistically significant numbers of mice. In addition, the (CRM+) 
R333Q mice  have the human factor IX R333Q gene expressed with  the alanine form of 
the Ala148Thr dimorphism, allowing for selective antibody detection between multiple 
variants of FIX [34].  These mice also have less than 1% clotting activity while having 
normal levels of FIX. Antibodies have been developed to detect both the infused FIX 
while ignoring endogenous R333Q-FIX and the total of all FIX in the sample, allowing 
for independent detection of the various FIX species in a given sample [34, 35] which 
allows for detection of the potential endothelial reservoir effects.   
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The majority of CRM- mice and 1 of 2 dogs exhibited increased coagulation and 
activity levels detectable one hour after feeding of raw tg-FIX pig milk.  The 
bioavailability of the biologically active tg-FIX was >10-fold higher in the single 
responding dog than any of the responding mice.  Interestingly, the bioavailability of tg-
FIX antigen into plasma circulation was similar for mice and dogs.  While a lipemic 
effect from the fat-rich pig milk might be increased in dogs over mice, the non-
responding dog had no increase in plasma coagulation activity after ingesting the same 
amount of pig milk.  Another explanation is the more selective absorption of biologically 
active tg-FIX from the milk, which contained only 10 to 15% biologically active tg-FIX.  
Indeed the specific activity of this additional circulating FIX was estimated to be 211 
IU/mg, which corresponds to that typically found for tg-FIX that is highly purified from 
the same raw milk [22, 23].  Thus, unlike the mice, the tg-FIX delivered into circulation 
is primarily selective for biologically active tg-FIX.  The dog antigen and coagulation 
activities were expressed as relative increases as both assays contained relatively high 
background levels.  Thus, the amount of dog FIX displaced from the endothelial 
reservoirs was not able to be determined.   
Because of the crude, less defined nature of tg-FIX when delivered from milk, we 
explored the use of highly purified CaP:tg-FIX and CaP:pd-FIX for use via buccal 
delivery. The formulation of CaP:FIX microparticles proved to be highly efficient.   
While the dose of 2000 IU/kg body weight was exceedingly high, the majority of normal 
mice studied (n=5) responded with easily observable and similar rises in the levels of FIX 
antigens after delivery of CaP:pd-FIX. The clearance of antigen lasted over 72 hours with 
a mean residence time of 17 hours, indicating that the mouse developed no negative 
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reaction to treatment and that the clearance phenomenon was not unlike that of 
endogenous FIX.   
This led us to examine similar dosing in CRM+ mice using the CaP:tg-FIX which 
resulted in similar response to buccal delivery of pd-FIX by the normal mice treatment  
study.  There was <1% activity in the coagulation assays of all treatment groups in the 
CRM+ mice, but the presence of antigen rise similar to buccal delivery of pd-FIX in 
normal mice indicates that a large amount of inactive FIX is stored in the endothelial 
reservoir and that the inactive FIX is displaced by the buccally delivered FIX, albeit by a 
small total rise in the levels of R333Q.  A significantly decrease in amount of bleeding 
occurring at 24 hours post-administration was observed only in the 6000 IU/kg mice 
indicating that only a very small amount of tg-FIX was present in the reservoir at 24 
hours.  
Thus, this study showed that buccal and oral administration of FIX significantly 
increases FIX concentration in the plasma during animal studies.  The >1% 
bioavailability of tg-FIX in oral delivery to a normal dog using crude milk as a 
formulation vehicle, shows a potential to utilize  the >100 fold abundance of FIX that 
transgenic livestock production can provide.  However, purified and well defined 
preparations of tg-FIX back-formulated into a defined, pasteurized milk vehicle would 
likely be necessary for the reproducibility needed for safe and efficacious 
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5.1 Abstract 
Background: Factor IX (FIX) is a member of the vitamin K-dependent (VKD) family of 
plasma glycoproteins which have a conserved γ-carboxyglutamic acid (Gla) domain that 
contains four Ca2+, three Mg2+, and one interchangeable divalent-metal binding sites. FIX 
also contains a Ca2+ binding site in both the EGF-1 like and catalytic domains.  In 
contrast to previous studies using protein fragments, this study quantifies the compaction 
of factor IX (FIX) holoprotein by Ca2+ and Mg2+. 
Methods: A novel application of high pressure size exclusion chromatography (HPSEC) 
taken together with analytical ultracentrifugation (AUC) and molecular modeling were 
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used to quantify overall compaction in the FIX holoprotein caused by divalent metal 
binding. 
Results: Over the range of sub- to physiologic levels of Ca2+, we observed a stark 
compaction of FIX associated with Ca2+ and Mg2+ binding.  The holoprotein compaction 
caused by the filling of Ca2+ sites was equivalent to a change in the radius of hydration by 
5-6% and similar to the changes in radius of gyration predicted by molecular modeling of 
the holoprotein. The compaction induced by physiologic levels of Ca2+ alone is greater 
than for Mg2+ alone and the presence of both divalent metals provided a cooperative 
increase in compaction.  
Conclusion:  The divalent metal-induced compaction phenomenon primarily arises from 
conformational changes in the core Gla domain and secondarily in the EGF1-like domain 
that is directly observable in the holoprotein by HPSEC.  
General Significance: This study provides a quantitative solution phase perspective to the 
metal dependent conformational attributes of the VKD holoproteins. 
 
5.2 Introduction 
The Vitamin K-dependent (VKD) family of  plasma proteins are key participants 
in the coagulation cascade of hemostasis[1, 2]. The first nine amino terminal glutamic 
acids of these glycoproteins are well conserved and are γ-carboxylated to form “Gla 
residues”.  These residues are part of the “Gla domain” that is essential to the function of 
VKD proteins. This family includes the anticoagulant proteins C, S and Z, and the 
procoagulant factors (F) VII, IX, X and prothrombin [3].  The core Gla domain contains 
seven to eight total divalent metal binding sites [4-11]: in the absence of Mg2+ all of these 
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sites could be occupied by Ca2+. However, higher than physiologic Ca2+ concentrations 
are needed for full occupancy of these sites. In the presence of physiologic Ca2+ (~1.1 
mM) and Mg2+ (~0.6 mM), four sites (numbered 2, 3, 5 and 6) are occupied by Ca2+ and 
three (numbered 1, 4, and 7) by Mg2+ [4, 10]. It is important to note that all metal sites in 
the Gla domain will be filled by Ca2+ at greater than 2 mM in the absence of Mg2+.  The 
Mg2+-site 4 is predicted to switch to Ca2+ upon binding of the Gla domain to phospholipid 
(PL) [11].  The conformational attributes of the isolated Gla domains have been well 
studied using NMR and x-ray crystallography [4, 5, 7-9, 12]. The Gla domain has also 
been studied using divalent metal, conformational-dependent monoclonal antibodies [13-
16]. Collectively, these previous studies have observed the localized and cooperative 
folding of the Gla domain with respect to the filling of Ca2+- and Mg2+-binding sites [17].  
FIX is a key VKD protein that consists of an N-terminal Gla domain followed by 
two epidermal growth factor-like domains and a C-terminal serine protease domain [1, 2]. 
It uniquely possesses a total of 12 Gla residues, but has a core Gla domain behavior 
typical of VKD coagulation proteins [18, 19]. With respect to other VKD coagulation 
proteins, FIX contains an additional divalent metal binding site that occurs outside of the 
core Gla domain; two additional Gla residues occur at amino acid positions 36 and 40 
and participate in the formation of an eighth Mg2+ site [9, 19].  The absence of these Gla 
residues in under-carboxylated recombinant versions of FIX has indicated that the 
number eight metal binding site occupied either by Ca2+ or Mg2+ does not contribute to 
FIX biological activity associated with PL binding [19]. FIX also contains two additional 
Ca2+-binding sites, one in the EGF1-like domain [20, 21] and the other in the protease 
domain [22, 23]. These two non-Gla divalent metal sites are specific for Ca2+ and 
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contribute to the structural and functional integrity of the molecule [21, 23]. During blood 
coagulation, FIX is converted to FIXa by FXIa as well as by the complex of FVIIa and 
cell surface tissue factor [1, 2]; both of these reactions require the divalent metal-
dependent folded structure of the Gla domain of FIX [24, 25]. FIXa thus formed activates 
FX to FXa; for a biologically significant rate, this reaction requires Ca2+/Mg2+ [26], PL 
(provided by platelets and the damaged endothelium) and FVIIIa [2]. These studies point 
out the role of individual domains in FIX and their importance in biologic function.       
The solution phase transitions of VKD coagulation proteins which are divalent 
metal dependent have been detailed for FII and FIX using spectroscopic and fluorometric 
measurements [27-29]. However, these transitions have not been well detailed using 
molecular size measurements of the whole protein.  Previous studies were not designed to 
quantify compaction of FIX in solution due to Ca2+ and Mg2+. Studies of this type have 
typically been attempted using circular dichroism [30, 31], light scattering [30], and/or 
analytical ultracentrifugation (AUC) [31-34]. Molecular size studies of PC [35], FVIIa 
[34], FIX [30, 32], FIXa [33], and fragments of FII [31] were limited and frequently 
complicated by the tendency to form aggregates when studied by AUC [31]. In the 
present study, we use HPSEC, AUC and molecular modeling to elucidate changes in 
molecular size that are induced in FIX by the filling of Ca2+- and Mg2+ -specific sites 






5.3 Materials and Methods 
Reagents  
All buffer components were purchased from VWR International LLC (Radnor, 
PA, USA) or Thermo Fisher Scientific (Waltham, MA, USA) or Sigma (St. Louis, MO, 
USA) unless otherwise stated. In order to minimize degradation, purification processes 
were performed at 4?C. The stocks of plasma-derived, therapeutic grade FIX (Mononine, 
CSL Behring, USA) were expired for clinical use, but when used in experiments, 
exhibited full procoagulant activity by one stage clotting assay. 
Size Exclusion Chromatography (SEC)  
The FIX product was concentrated and exchanged into 20 mM Tris, 200 mM 
NaCl, pH 7.0 (SEC/Injection running buffer) using an Amicon Ultra 10 kDa molecular 
cut-off centrifugal filter (Millipore, Billerica, MA, USA). Both the SEC/Injection running 
buffer was treated with the sodium form of Analytical Grade Chelex 100 resin (Bio-Rad 
Laboratories, Hercules, CA USA) to remove any divalent metal contamination.  Some 
running buffer studies contained CaCl2 and or MgCl2 that was added after Chelex 100 
resin treatment while all injection samples contained divalent metal-free buffer. The FIX 
was loaded onto a 60 cm X 2.15 cm I.D. TSK gel G3000SW column (Tosoh Bioscience, 
King of Prussia, PA, USA) equipped with a guard column and a pre-filter.  
Briefly, the chromatography was performed on the Knauer (Berlin, Germany) 
Smartline chromatography station described above. The flow rate was set at 0.5 mL/min 
and the run length was 45 minutes. Effluent’s absorbance was measured at an absorbance 
of 280 nm. Samples were run in triplicate and the centers of the elution peaks were used 
to calculate residence time (with standard deviation <0.016).  
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 Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples were analyzed by SDS-PAGE stained with colloidal blue gel stain 
(Invitrogen, Carlsbad, CA, USA) using Invitrogen Novex precast gels and the Invitrogen 
Surelock XL apparatus. All gels were NuPage 12% Bis-Tris run with 2-(N-morpholino) 
ethanesulfonic acid (MES) running buffer (Invitrogen). Briefly, samples were mixed with 
4x LDS sample buffer (Invitrogen) and deionized water followed by heating at 75 ◦C for 
10 min. For reduced gels, samples were mixed with 10x reducing agent (Invitrogen) prior 
to heating. 
Analytical Ultracentrifuge 
FIX in 0.15 M NaCl, 50 mM Tris, pH 7.5 with either 10mM EDTA or CaCl2 
and/or MgCl2 was examined by sedimentation velocity in a Beckman Optima XL-A 
analytical ultracentrifuge at 52,000 or 55,000 rpm and 20 oC in 12 mm path length double 
sector cells using absorption optics at 280 nm.  All samples were at the same protein 
concentration, 0.3 mg/mL.  Apparent sedimentation coefficient distributions, uncorrected 
for diffusion, were determined as g(s) plots using the Beckman Origin based software 
(Version 3.01).  These plots display a function proportional to the weight fraction of 
material with a given sedimentation coefficient, s.  The function g(s) was calculated as: 
 
g(s) = (dc/dt)(1/co)(2t2/ln(rm/r))(r2/rm2); 
 
where s is the sedimentation coefficient,  is the angular velocity of the rotor, co is the 
initial concentration, r is the radius, rm is the radius of the meniscus, and t is time.  The x-
axis is converted to sedimentation coefficient by: 
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 s = (1/2t)(ln(r/rm)) 
 
These plots display a function proportional to the weight fraction of material with a given 
sedimentation coefficient, S [36].  The peak sedimentation coefficients were corrected for 
density and viscosity of the solution to S20,w values. To perform this correction, a value of 
0.708 for the partial specific volume calculated from the amino acid and carbohydrate 
composition was used [37, 38]. This correction is quite insensitive to the value for the 
partial specific volume in this range.  The Stokes radius was calculated using a molecular 
weight of 62,800 and a partial specific volume of 0.708. 
Modeling of Divalent Metal-Free and Bound FIX 
The equilibrated solution structures of the zymogen form of metal bound FIX 
were obtained from Perera [39]. The MODELLER program [40] was employed to model 
the metal-free FIX zymogen structures utilizing the metal bound zymogen structures and 
the NMR structure of metal-free FIX Gla domain (pdbid 1CFX,[12]) as templates. The 
built models were further refined by energy minimization using the CHARMM program 
with CHARMM19 force field [41] consisting of 50 steps of Steepest Descent, followed 
by 500 steps of Adopted Basis Newton-Raphson. Harmonic restraints of 10 kcal/mol/Å2 






5.4 Results and Discussion 
 FIX compaction induced by divalent metals predicted by molecular modeling  
We first used molecular modeling to predict the nature and magnitude of the size 
change that would be induced by the filling of divalent metal binding sites within the FIX 
holoprotein structure. The modeled structures of the zymogen form of divalent metal-free 
and metal bound FIX are shown in Fig 5.1. This modeling effort employs no assumptions 
of shape, but a linear molecule is predicted for both divalent metal containing and under 
metal-free conditions. Thus, we use the model to predict a radius of gyration rather than a 
Stokes Radius (R) from the spherical assumption used to estimate changes in compaction 
using AUC. The radius of gyration values for the modeled structures of metal-free FIX is 
34.46 Å while the radius of gyration value for the metal bound FIX is 32.75 Å. The 
change in radius of gyration between the metal bound and metal-free states of FIX is 
~5%.  As expected, the major transitions in structure arise from the Ca2+/Mg2+ binding to 
the Gla domain of FIX (Fig 5.1A, 5.1B). Furthermore, the Ca2+ binding sites exterior to 
the Gla domain that occur in the EGF-1 [20] and protease domains [22, 23] are predicted 
to give much smaller contributions to compaction due to occupation of Ca2+ at those 
sites. It is known that the folding of the Gla domain is both Ca2+/Mg2+ dependent [10, 12, 
16, 42-44] and without these divalent ions, the Gla domain is in a completely unfolded 
state [12]. General conformation changes have been observed in all the coagulation 
proteins earlier in fluorescence quenching and metal binding studies [12, 30, 42]. 
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Figure 5.1. Modeled structures of intact FIX without (A) and with (B) divalent metal ions predicted 
from the crystallographic data. The Gla, EGF1-like, EGF2-like and the protease domain in FIX are 
colored red, yellow, purple and cyan, respectively.  FIX contains 10 Ca2+/Mg2+ binding sites, which are 
numbered 1 through 10; eight of these are in the Gla domain (number 1-8), one in the EGF1-like domain 
(number 9) and one in the protease domain (number 10).  The Ca2+-specific sites are shown as green 
spheres, whereas the sites 1, 4, 7 and 8  could be occupied by either Ca2+ or Mg2+ are shown as magenta 
spheres. As a result of divalent metal binding, a major structural change occurs in the Gla domain and a 
minor change in the EGF1-like domain of FIX.  The properly formed ω-loop is clearly visible and 
positioned below metal sites 3, 4 and 5. 
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Homogeneity and extent of aggregation of the plasma derived FIX studied 
We assessed both the homogeneity of the FIX and extent of protein aggregation 
that potentially could occur in the range of metal and protein concentrations studied here. 
Previous studies have reported protein aggregation in FIX in the presence of divalent 
metals observed by AUC at concentrations of >0.3 mg FIX/mL [30].  Fig. 5.2A shows 
analysis by SDS-PAGE under non-reducing conditions of immunoaffinity purified, 
therapeutic grade FIX. As has been well documented for preparations of plasma-derived 
FIX, the FIX studied here contained a proteolyzed FIX species of the Mr 47 kDa having a 
10 kDa fragment removed from its carboxy-terminus known as FIXγ[45].  We estimated 
the FIX to be >95% zymogen having a Mr of 57 kDa and contained <5% proteolyzed 
FIX. Fig. 2B and 2C show the typical HPSEC chromatographic profiles for injections of 
25 and 50 μg FIX that was obtained at physiologic pH in the presence of 1.1 mM Ca2+ 
alone and of 0.6 mM Mg2+ alone, respectively. Fig. 5.3-5.5 present the HPSEC 
chromatographic behavior for analysis of 100 μg injections. In all cases studied, the 
HPSEC behavior possessed a single predominant and symmetrical peak. In the case of 
the 100 μg injection, a peak height signal was observed, which was about 4- and 2-fold 
larger than those observed for the 25 μg and 50 μg injections. Furthermore, other than the 
main peak only a few peaks of less than 15% intensity of the main peak were observed. 
Taken together, these studies show that these samples predominately contained intact FIX 
zymogen and that there was no appreciable tendency of the FIX to form aggregates at any 
of the divalent metal or protein concentrations examined here by HPSEC or AUC.  
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Figure 5.2. Homogeneity and extent of aggregation of starting samples of purified FIX. SDS-PAGE 
and HPSEC as a function of the injection amount was studied: A) Non-reducing SDS-PAGE of purified 
FIX: Lane 1.  Molecular weight markers; Lane 2. FIX (2 μg). B) HPSEC chromatographic profiles of FIX 
at 25 μg (curve 1) and at 50 μg injected (curve 2) at physiologic 1.1 mM Ca2+ and C) HPSEC 
chromatographic profiles of FIX at 25 μg (curve 1) and at 50 μg injected (curve 2) at physiologic 0.6 mM 
Mg2+.   
 
 Ca 2+-specific compaction of FIX observed by HPSEC 
We investigated the effect on FIX macromolecular size caused by the filling of 
divalent metal specific sites when chromatographed at physiologic pH and various levels 
of Ca2+ alone using HPSEC. While in the absence of Mg2+, all sites in FIX Gla domain 
can be occupied by Ca2+,  positions 1, 4, 7 and 8 are occupied by Mg2+ at physiologic 
levels of Ca2+ and Mg2+. However, at supraphysiologic levels of Ca2+ in vitro, Mg2+ at 
site 4 is displaced by Ca2+ [11]. Fig. 5.3A shows the HPSEC chromatographic profiles for 
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FIX collected over a range of sub- to supra-physiologic Ca2+ levels in the absence of 
Mg2+. Under this condition, each divalent metal binding sites has the potential to be 
occupied by Ca2+. A baseline residence time of about 17.1 minutes was obtained for the 
elution peak of FIX in a chelated environment (Fig. 5.3A: curve 1).  When 
chromatographed at a subphysiologic level of 0.5 mM Ca2+, the residence time shifted 
markedly to a longer time of 17.9 minutes (Fig. 5.3A: curve 2). Importantly, this signifies 
a compaction response at a Ca2+ level that completely fills each of the single Ca2+ specific 
sites that occurs within the EGF1-like and the catalytic domain.  At the physiologic 
concentration of 1.1 mM Ca2+ (Fig. 5.3A: curve 3), the residence time of FIX was 
markedly shifted to 18.2 minutes. This correlates with the near half maximal filling that is 
known to occur within the four to five Ca2+ sites of the Gla domain [43]. A further and 
substantial shift was observed at the supra-physiologic level of 5 mM Ca2+ (Fig. 5.3A: 
curve 4) resulting in a longer residence time of 18.6 minutes. When FIX was 
chromatographed at 10 and 15 mM Ca2+, similar residence time shifts of about 19 and 




Figure 5.3 HPSEC residence time behavior of FIX in the presence of CaCl2 only. In each case, amount 
of FIX injected was 100 g. A) Curve 1: no divalent metal, Curve 2: 0.5 mM CaCl2, Curve 3: 1.1 mM 
CaCl2, Curve 4: 5 mM CaCl2, Curve 5: 10 mM CaCl2, Curve 6: 15 mM CaCl2.  B) Net residence time shift 
in the HPSEC residence time by FIX with change in CaCl2 concentration in the range from 0 - 15 mM; 
inset, magnified view of residence time shift induced  in the range from 0 – 0.5 mM CaCl2. Each data point 
condition was performed in triplicate with a standard deviation <0.016 minutes. 
 
Relative to that of a chelated environment, two distinct Ca2+-specific compaction 
regimes are apparent in a plot of the net residence time shift versus Ca2+ concentration 
(Fig. 5.3B).  A compaction regime reflecting interactions with higher affinity Ca2+ sites is 
seen spanning the range of about 0.1 to 0.3 mM Ca2+ (Fig. 5.3B: inset plot).  Thereafter, a 
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shift occurs at about 0.3 to 5 mM which is consistent with the past reported filling of 
divalent metal sites within the Gla domain. The Gla sites have lower avidity for Ca2+ than 
each of the individual sites occurring within the catalytic [22, 43] and EGF1-like domains 
[21]. Thus, the compaction behavior of FIX observed at supra-physiologic levels of Ca2+ 
is likely the combined filling of both high avidity Ca2+-specific sites in the EGF-like and 
protease domains along with the lower avidity Ca2+ sites of the Gla domain.  It must be 
noted that in the absence of Mg2+, all sites are occupied by Ca2+ at ≥2 mM [11].   
Mg2+-specific compaction of FIX observed by HPSEC 
We investigated the effect on FIX macromolecular size caused by the filling of 
divalent metal specific sites when chromatographed at physiologic pH and various levels 
of Mg2+ alone using HPSEC.  Based upon our molecular modeling and structure of FXa 
in the presence of Mg2+ only, the effect on molecular size is expected to be less for Mg2+ 
than Ca2+ both due to the positioning [9-11] and the presence of only four (number 1,4,7, 
and 8) Mg2+-sites in the Gla domain of FIX [46].  The HPSEC chromatographic profiles 
of FIX in the presence of Mg2+ alone are shown in Fig. 5.4A. In these experiments, a 
baseline residence time of about 17.0 minutes was obtained for the elution peak of FIX 
under chelating conditions (Fig. 5.4A: curve 1). The presence of the physiologic level of 
0.6 mM Mg2+ resulted in a small but significant residence time shift to a longer time of 
17.3 minutes (Fig. 5.4A: curve 2).  Past studies have shown that all four Mg2+-specific 
sites within the core Gla domain of FIX (three in other VKD coagulation proteins and 
Protein C) are at least half maximally filled at physiologic levels of  Mg2+ [47].  At supra-
physiologic Mg2+ concentrations of 5, 10 and 15 mM Mg2+ the residence time further 
shifted to 17.6, 17.7, and 17.7 minutes, respectively (Fig. 5.4A: curves 3, 4, and 5 
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respectively). The asymptotic behavior of the response to supra-physiologic levels of 
Mg2+ is easily seen in a plot of the net residence time shift versus Mg2+ concentration 
(Fig. 5.4B). A much smaller compaction resulted when FIX was chromatographed in the 
presence of Mg2+ versus Ca2+ alone.  This reduction in compaction response is consistent 
with the peripheral position and lesser number of Mg2+ sites within the core Gla domain 
(Fig. 5.1B).    
 
Figure 5.4. HPSEC residence time behavior of FIX in the presence of MgCl2 only.  In each case, the 
amount of FIX injected was 100 g. A) Curve 1: no divalent metal, Curve 2: 0.6 mM MgCl2, Curve 3: 5 
mM MgCl2, Curve 4: 10 mM MgCl2, Curve 5: 15 mM MgCl2. B) Net residence time shift in the HPSEC 
residence time by FIX with change in MgCl2 concentration in the range from 0 - 15 mM. Each data point 
condition was performed in triplicate with a standard deviation <0.016 minutes. 
FIX compaction resulting from presence of both Mg2+ and Ca 2+ observed by HPSEC 
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The chromatographic data obtained in the presence of Ca2+ or Mg2+ alone showed 
that two different extents of compaction exist that are consistent with the highly Ca2+- or 
Mg2+-specific nature of the divalent metal binding sites within FIX. We investigated the 
interdependence of the compacted conformation resulting from the presence of both 
divalent metals: Fig. 5.5 shows the HPSEC chromatographic profile of FIX in the 
presence and absence of both physiologic levels Ca2+ and Mg2+ as well as presence of 
Ca2+ or Mg2+ alone at physiologic levels. We observed that the FIX residence time in the 
presence of both Mg2+ and Ca2+ at physiologic conditions (Fig. 5.5: Curve 4) was longer 
than that obtained in the presence of no divalent metal (Fig. 5.5: curve 1), 0.5 mM Mg2+ 
alone FIX (Fig. 5.5: curve 2) and 1.1 mM Ca2+ alone (Fig. 5.5: curve 3).  While the 
residence time for Mg2+ is much smaller than for Ca2+ alone, the SEC residence time shift 
resulting from the simultaneous presence of both divalent metals is essentially additive. 
With respect to the Gla domain, this indicates that at physiologic levels of Mg2+ and Ca2+, 
there is little competition between divalent metal ions for sites that induce compaction. 
This is consistent with the compaction predicted by our molecular modeling (Fig. 5.1) 
where the divalent metal sites 2, 3, 5, and 6 of FIX of the Gla domain are occupied by 
Ca2+ while sites 1, 4, 7 and 8 are occupied by Mg2+ [6, 9-11].  In contrast, the additive 
effect on compaction in the presence of physiological levels of both Ca2+ and Mg2+ was 
not detected by AUC. Previous literature on the effect of calcium on factor IX detected an 
expansion in FIX when calcium concentration was raised [30] By removing the effects of 
increased concentration and the corresponding aggregation, this new data reveals the 
compaction of FIX due to the filling of metal binding sites. 
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Figure 5.5. HPSEC residence time behavior of FIX in the presence of physiologic levels of both CaCl2 
and MgCl2. Curve 1: no divalent metal, Curve 2: 0.6 mM MgCl2, Curve 3: 1.1 mM CaCl2, Curve 4: 1.1 
mM CaCl2 & 0.6 mM MgCl2. Each data point condition was performed in triplicates with a standard 
deviation <0.016. 
 
It is noted that the physiologic significance of the compaction of FIX resulting 
from the filling of the divalent metal binding sites within the Gla domain is profoundly 
embodied by the organization and formation of the ω-loop. The ω-loop is clearly seen in 
Fig. 5.1B.  Divalent metal sites 2 to 6 strongly affect the positioning of the ω-loop which 
spans amino acids 1-14 and is central to phospholipid binding. Upon binding of 
phospholipid, site 4 is converted from a Mg2+ to a Ca2+ site, which results in profound 
repositioning of the ω-loop to the interior of the Gla domain [6, 9-11].  Supra-physiologic 
concentrations of Ca2+ can also result in the filling of site 4 by Ca2+ and a repositioning of 
the ω-loop.  
Analytical ultracentrifuge studies of the compaction of pd-FIX induced by divalent metals  
The HPSEC results presented above indicate a divalent cation induced 
compaction of FIX. We use AUC to both confirm the general compaction phenomena 
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and to calibrate the observed HPSEC chromatographic behavior for the correlative 
estimation [48-50] of the Stokes hydrodynamic radius (R) at the divalent metal ion 
concentrations studied here. It is important to note that past AUC studies of VKD 
coagulation proteins in the presence and absence of divalent metal did not statistically 
evaluate compaction phenomena, but were specifically used for the purpose of examining 
the presence or absence of aggregation. Table 5.1 provides the sedimentation coefficient 
(s) and calculated R values which were obtained by AUC for FIX in the absence and 
presence of physiologic levels of Ca2+ and Mg2+. R is inversely proportional to the 
sedimentation coefficient, S20,w, where compaction of the FIX increases the 
sedimentation coefficient. Specifically, the sedimentation coefficient s was used to 
calculate the Stokes Radius defined by the relationship: 
 
s = [(M)(1-ṽ)()] / [(N)(6	
	R)]  
 
where M is the molecular weight, ṽ is the partial specific volume,  is the solvent density, 
N is Avagadro’s Number and 
 is the viscosity [51].   
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Table 5.1. Sedimentation coefficients and estimated Stokes radii from analytical centrifugation of FIX. The 
sedimentation coefficient S is given for FIX centrifuged in the presence of EDTA, Ca2+ and/or Mg2+. 
Solvent1 
S20,w 
(Svedberg) Stokes Radius (nm) 
10 mM EDTA2 3.71 4.36a 
10 mM EDTA 3.72 4.35a 
10 mM EDTA 3.72 4.35a 
0.6 mM MgCl2 3.82 4.24 
0.6 mM MgCl2 + 1.1 mM 
CaCl2 3.83 4.23 
0.3 mM CaCl2 3.82 4.24 
1.1 mM CaCl2 3.85 4.21a 
3.0 mM CaCl2 3.89 4.16 
aUsed to determine coefficient of the SEC correlation by methods developed in  Laurent and Killander 
(1964). 
1 The buffer contained 50 mM Tris, 0.15 M NaCl, pH 7.5  and the indicated reagent. 
 2 Molecular weight of 62,800 Da and a partial specific volume of 0.708 for FIX were used in these 
calculations. 
 
We observed an S20,w of 3.72 ± 0.006 Svedburgs (n=3) by AUC in 10 mM EDTA 
at 0.3 mg FIX/mL and this translates to an estimated R= 4.35 nm ± 0.006. Previously 
reported S20,w values were 4.17  Svedburgs for FIX measured in the presence of 2 mM 
EDTA and also for 2.5 mM Ca2+ [30]. Thus the value was larger than those reported here 
and the previous studies made no conclusions concerning the compaction induced by the 
presence of Ca2+. Since Ca2+ was a predominant and largely independent variable 
associated with the observed compaction by HPSEC, we used the AUC observations 
obtained for 1.1 mm Ca2+ with or without Mg2+ as a statistical group for estimating its 
impact of the presence of Ca2+ on S20,w :  we obtained a value  S20,w = 3.84 ± 0.014 
Svedburgs (n=2) corresponding to R= 4.22 nm ± 0.014. Thus, the sedimentation obtained 
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by AUC supports a predominant and stark compaction effect by Ca2+ both observed by 
HPSEC and predicted by molecular modeling.  
 Estimation of the amount of compaction observed by SEC 
We further used the values of R obtained by AUC for metal-free FIX (in EDTA) 
and the data point at presence of 1.1 mm Ca2+ to estimate column parameters needed to 
predict the change in R from all other HPSEC data.  The correlation of Fish et al. [50] has 
been used to efficiently predict the R value behavior of many different proteins using size 
exclusion chromatographic behavior found in agarose [49] and Sepharose [48, 49] 
packings as well as the TSK 3000SW used in this study [52]. Fig. 5.6 shows a strong 
interpolative consistency for the R vs. Ca2+ concentration behavior using HPSEC values 
in the range of 0 to 1.1 mM Ca2+. These values were very consistent with our 
experimental values obtained by AUC that were not used to predict column parameters. 
At a physiologic level of Ca2+ which is equal to or greater than that needed for half 
maximal filling of Ca2+ specific sites in the Gla domain, the overall change in R of FIX is 
about 2.7 % relative to the metal-free FIX. Furthermore, the HPSEC behavior that results 
from the complete filling of Ca2+ sites at supraphysiologic levels predicted an asymptotic 
compaction of about 5.6% change in R. The change in the radius of gyration predicted by 
our modeling was similar at about 5%.  In summary, the quantitative compaction 
phenomena in the range of 0 to 15 mM Ca2+ measured by both AUC, HPSEC and the 
modeling of this work with consistent with each other and also the complete Ca2+ site 
filling within the Gla domain from equilibrium dialysis [43].   
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Figure 5.6. Estimated CaCl2-dependent change in Stokes radius of FIX as measured by HPSEC. R 
values by HPSEC made by the correlation method of Laurent and Killander [33], Acker [34], and Fish and 
Reynolds et al. [35]. Circled data points at 1.1 mM CaCl2 and 0 mM divalent metal indicates the 
experimental SEC and AUC values, which were used to calibrate column parameters.  SEC Value;  
AUC Value;  Percent change in R estimated by SEC (%). 
 
5.5 Conclusion 
This is first direct observation of the VKD coagulation protein compaction.  
HPSEC was used to obtain a quantitative, solution phase assessment of the 
conformational effects on the overall macromolecular size of FIX that can be attributed to 
the independent filling of the high affinity Ca2+ specific sites of the EGF1-like and 
protease domains along with the Ca2+ and Mg2+ sites of the Gla domain. Molecular 
modeling indicates that the predominant source of compaction results from the change in 
conformation for the Gla domain and secondarily from the EGF1-like domain due to site 
filling by Ca2+. A similar compaction likely occurs with other VKD coagulation proteins 
due to the well conserved core Gla domain of this family.  
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Human factor XIII (FXIII) is activated by thrombin during fibrin formation, releasing a 
dimeric, transglutaminase (FXIIIA2a) which both converts fibrin into a crosslinked, viscoelastic 
barrier and covalently anchors it to wound surfaces.  Past examples of expression in yeast resulted in a 
secreted dimeric recombinant (r-) FXIIIA2 zymogen. An expression cassette using the cDNA for r-
FXIII catalytic subunit A-chain (r-FXIIIA) with His-tag sequences at both amino- and carboxy-
terminii was inserted into Pichia pastoris. The r-FXIIIA was recovered from cell lysate, purified by 
immobilized metal affinity chromatography (IMAC), and evaluated by SDS-PAGE, Western analysis, 
amino terminal sequencing, size exclusion chromatography (SEC), and a chromogenic assay for 
transglutaminase activity.  We characterized the kinetic and crosslinking properties of monomeric, 
recombinant FXIII subunit A (r-FXIIIA1) for both plasma-derived fibrinogen and recombinant 
fibrinogen purified from the milk of transgenic cows.  Pichia pastoris novelly formed an 81 kDa 
monomeric r-FXIIIA (r-FXIIIA1) while being expressed at >0.25 mg per gram of fermentation cell 
mass.  SEC showed monomeric r-FXIIIA1 was the predominant purified species where SDS-PAGE, 
amino terminal sequencing, and anti-His-tag Western showed that the amino terminal His-tag 
activation peptide sequence was removed; however, the carboxy-terminal His- and myc-tags remained 
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in place, forming an artificial, kinetically-favorable thrombin-sensitive activation peptide. The r-
FXIIIA1 had a ≥2-fold specific activity by chromogenic assay than plasma-derived (pd-) FXIIIA2, and 
thromboelastography determined that fibrin sealant formed with the r-FXIIIA1 reached the same 
maximum amplitude fibrin sealant without FXIII 15 minutes faster. The unique in situ processing of 
the r-FXIII catalytic subunit to form a fully functional r-FXIIIA1 by the P. pastoris production system 
can potentially provide a dose-dependent abundant source of transglutaminase with higher specific 
activity and kinetically enhanced crosslinking. 
6.2 Introduction 
Human factor XIII (FXIII) is a coagulation protein that circulates in plasma and is also 
displayed on the surface of platelets [1]. FXIII performs the essential hemostatic tasks of 
intrachain crosslinking needed to form insoluble fibrin and the concomitant anchoring of the 
fibrin hemostatic plug to wound surfaces. The transglutaminase activity of enzymatically 
activated FXIII (FXIIIa) serves to crosslink other proteins to fibrinogen (FI) or fibrin. Some of 
these proteins are necessary for clot stabilization and adherence of the clot to the lesions in blood 
vessel walls [2] and include: α2-antiplasmin and fibrinogen to confer resistance to fibrin clot lysis 
by plasmin [3], fibronectin and fibrin for cell recruitment during wound healing  [4-6], fibrin and 
extracellular matrix collagen [4, 7], von Willebrand factor and fibrin and/or collagen [8, 9] 
associated with activated platelet wound adhesion. 
Plasma-derived (pd-) FXIII is a 326 kDa tetrameric, non-covalent complex consisting of 
a homodimer of two identical catalytic A-chains (FXIIIA2) that is packaged by two identical B-
chains [2, 10-12]. The A2 subunit alone is displayed on the surface of platelets as part of the 
mechanism to incorporate both fibrin and activated platelets into primary hemostatic plug. The 82 
kDa A-chain [13-15] is hydrophobic and synthesized by hepatocytes, monocytes and 
megakaryocytes [13-15]. In the case of plasma-borne tetrameric FXIII, the B-chains are secreted 
into plasma by hepatocytes as single chains, where some form complexes with the A-chain [15] 
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and others circulate freely [2]. Each chain in the A2 subunit of plasma or platelet FXIII can be 
activated by thrombin to form activated FXIIIA2 (FXIIIA2a) [1, 16-18]. The enzymatic 
activation of the A2 by thrombin releases a 4.5 kDa activation peptide [19] after  cleavage at 
Arg37-Gly38 [20, 21].  The A2 of tetrameric FXIII is stabilized by the B-chains and therefore are 
more slowly activated by thrombin than that of A2 displayed on platelet surfaces [22-26]. 
Specifically, the interactions of the B-chains with fibrin and calcium ions cause the dissociation 
of the B-chain to form free A2 prior to its activation [17, 21, 22, 27-29]. Feedback control over 
FXIIIA2a activity is made by further proteolysis by thrombin which cleaves the A-chain at 
Lys513 resulting in two fragments of 25 and 54 kDa [12],  resulting in FXIIIA2a inactivation.   
Human recombinant (r-) FXIIIA2 has been produced in Saccharomyces cerevisiae [30-32] for use 
in FXIII deficiency replacement therapy. It has also been produced in Pichia pastoris [33] and in 
transgenic plants [34] using the cDNA of FXIIIA.  The purified r-FXIIIA2 obtained from both 
plant and S. cerevisiae cell lysates were confirmed to be dimeric assemblies by measurements 
using analytical ultracentrifugation.  The FXIIIA cDNA expressed in P. pastoris was secreted but 
the extent of assembly into a dimer was not reported.  In each case, the activation of the r-
FXIIIA2 to form r-FXIIIA2a by human thrombin and then subsequent transglutaminase activity 
was demonstrated.  The S. cerevisae derived zymogen r-FXIIIA2 was shown to restore clot 
strength and provide lysis resistance in vivo [35]. This past study demonstrated that parenterally 
administered, therapeutic grade r-FXIII could be produced using intracellular expression in yeast 
fermentation.  However, r-FXIIIa has uses in recombinant fibrin sealants [36, 37].  We report on 
the production of monomeric, r-FXIIIA1 (r-FXIIIA1) containing an artificial activation peptide 
using intracellular expression in Pichia pastoris. 
6.3 Materials and Methods 
Materials 
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Plasma-derived human FXIII (pd-FXIII), human thrombin (pd-FIIa), and plasma-
derived fibrinogen (pd-FI) were bought from Enzyme Research Labs (South Bend, IN).  
Recombinant human thrombin (r-FIIa) was purchased from ZymoGenetics (Seattle, WA).  
Apolipoprotein E (APOE) recombinant human protein was purchased from Life 
Technologies (Grand Island, NY).  Purified recombinant fibrinogen (r-FI), expressed in 
the milk of transgenic cows, and was obtained from Pharming Group NV (Leiden, 
Netherlands).  PPACK was purchased from Haematologic Technologies (Essex Junction, 
VT). 
Expression vector construction and expression 
  The human Ultimate ORF clone containing the human coagulation FXIIIA1 
cDNA in the pENTRTM221 vector was purchased from Invitrogen (Clone ID: IOH11901, 
Carlsbad CA). The following primers were used to subclone the FXIIIA1 cDNA into the 







The forward primer introduced a methionine and six histidine amino acids (His-tag) at 
the N-terminal of mature FXIIIA1 peptide. The PCR product was digested with MfeI and 
NotI and subcloned into pPICZA, which was digested with the same enzymes (Fig. 
6.1A).  The 3’-His-tag encoding site within the pPICZA expression vector was retained 
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after insertion of the FXIIIA1 cDNA (Fig. 6.1). The sequence of the PCR amplified DNA 
of the yeast insertion indicated that the full and native FXIIIA1 cDNA was present with 
both 5’ and 3’ His-tag sequences in place.  One of the confirming plasmid pPICZA-
FXIIIA1 was linearized with PmeI and transformed into Pichia pastoris X-33 host strain 
and copy number of the clones was determined. Varying copy number clones were 
screened in a shake flask culture to confirm intracellular production of FXIIIA protein. 
The highest-producing clone was scaled up to 5 L bench scale.  A fed-batch fermentation 
protocol was followed to optimize FXIIIA1 production as described by Zhang et al. [38].  
At the end of the fermentation process the cells were separated by centrifugation 
(6,000xg) and the pellet was stored at -80oC. 
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Figure 6.1. Schematic description of parent r-FXIIIIA1 and observed cleavage products with the 
molecular weights of observed cleavage products. (A) Schematic of vector pPICZA-FXIIIA.  FXIIIA 
cDNA (2199 bases) with a His-tag (17 bases) on the N-terminal was inserted into the pPICZA vector 
containing a 5’ AOX1 promoter (941 bases), multiple cloning site (79 bases), Myc-tag (32 bases), His-tag 
(17 bases) and 3’ AOX1 transcription termination region (341 bases).  The restriction enzyme sites utilized 
are shown with orange arrows. (B) Schematic of the expected r-FXIIIA expressed by yeast, (C) r-FXIIIA1 
molecule purified from yeast cell lysate by IMAC, (D) cleavage products of r-FXIIIA1 when exposed to 
thrombin, and (E) degradation products of FXIIIA1 when exposed to r-FIIa.  FXIIIA is composed of a His-
tagged activation peptide (His-AP) (green, ~5.3 kDa) and the FXIIIa catalytic domain (blue, ~79 kDa).  
His-tags are designated in yellow (~0.8 kDa) and the Myc-tag in grey (~1.2 kDa).  The known thrombin 




Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste were resuspended in 100 mL of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 mL (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added.  Surrounded by an ice bath, cells were lysed using a BeadBeater Blender 
(Biospec, Bartlesville, OK) with twenty 20-second on/off cycles.  The cell lysate mixture 
was then centrifuged to remove cellular debris.  The lysate from 300 grams of cell paste 
was combined and purified using the HisBind Purification Kit (EMD Chemicals, Inc., 
San Diego, CA) with 40 mL of resin slurry.  Following purification by immobilized 
metal-chelate affinity chromatography (IMAC), the r-FXIIIA1 was diluted 2-fold in order 
to minimize aggregation and then dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM 
polysorbate-20, pH 8.0 in snake-like dialysis membranes and the protein samples were 
filter-sterilized and concentrated using the Amicon tubes (Millipore, Billerica, MA).  The 
purity of the sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Life 
Technologies, Carlsbad, CA) and immunoblot.  The concentration of r-FXIIIA1 was 
determined by standard Bicinconic Acid (BCA) methods [39].   
Comparison of r-FXIIIA1 with pd-FXIII by SDS-PAGE and Western blot  
Non-reduced and reduced FXIII samples (pd-FXIII and r-FXIIIA1) were 
evaluated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 
4-12% NuPage® Bis-Tris gels (Life Technologies, Carlsbad, CA).  Gels were then stained 
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with Colloidal Blue (Life Technologies) or electroblotted onto Immun-BlotTM 
polyvinylidene fluoride (PVDF) membranes (BioRad, Hercules, CA) for 
immunoblotting.  Blots were probed with an anti-His-tag monoclonal antibody 
(Invitrogen, Carlsbad CA) and anti-human FXIII Subunit A polyclonal antibody (US 
Biological, Swampscott, MA).  
Size exclusion chromatography  
Size exclusion chromatography (SEC) was used to characterize the extent of 
aggregation of the affinity purified r-FXIIIA1 though estimation of the Stokes radius (Rs) 
and the molecular weight [40].  Reference proteins of known Rs were used: Bovine serum 
albumin (Sigma, St. Louis, MO), human plasma-derived prothrombin, immunoglobulin A 
(IgA) (Sigma, St. Louis, MO) and immunoglobulin G (IgG) (Green Mountain 
Antibodies, Burlington, VT) were exchanged into 20 mM Tris-HCl, 200 mM NaCl, 60 
μM Tween 20, pH 7.0.  After being passed through a 0.20 μm nylon filter (Millipore, 
Billerica, MA), 0.5 mL of each sample were chromatographed through a TSK-
G3000SWxL (Tosoh Biosciences, South San Francisco, CA) column (14 mL, 30 cm 
length, 7.8 mm ID) attached to a Knauer HPLC System at 0.5 mL/min for 45 minutes and 
data were collected by a photodiode array (PDA) with a 1 mm flow cell and analyzed by 
EZChrom Elite software.  The affinity purified r-FXIIIA1 (0.5 mL at 1.94 mg/mL) in 20 
mM Tris-HCl, 200 mM NaCl, 60 μM Tween 20, pH 7.0 was also chromatographed using 
the same method.  The EZChrom Elite software was used to overlay the tracings and 
match the heights of the primary peaks. The Rs and relative molecular weight (Mr) of 
affinity purified r-FXIIIA1 was estimated using the method of Laurent and Killander [40] 
using SEC retention times of reference proteins with known Rs values.   
114 
Amino acid Sequencing and Activation and inactivation of pd-FXIII and r-FXIIIA1 by r-
FIIa 
The activation and inactivation the r-FXIIIA1 by r-FIIa was evaluated by SDS-
PAGE by a similar procedure previously described [30].  Reference pd-FXIII (final 
concentration: 0.31 mg/mL) was incubated with r-FIIa (0.03 U/mL) in Ringer’s solution 
(155 mM  NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) at 37oC.  Activation samples 
were incubated for 0, 0.5, 1.0, 1.5, 2, 3, 4 and 5 minutes.  Inactivation samples were 
incubated for 2 seconds, 5, 15, 30, 60, 120, 240 and 360 minutes.  Reactions were halted 
by the addition of NuPage® LDS sample buffer and NuPage® Sample Reducing buffer (β-
mercaptoethanol) (Life Technologies, Carlsbad, CA).  For the zero time point for the 
activation samples, FXIII and r-FIIa were added directly into sample buffer and reducing 
agent.  Samples were evaluated by sodium dodecylsulfate-polyacrylamide (SDS-PAGE) 
gel electrophoresis on 4-12% NuPage® Bis-Tris gels.  Gels were stained with Colloidal 
Blue or electroblotted onto PVDF membrane and stained with Colloidal Blue. Bands 
were excised and the first ten amino acids in the N-terminal were sequenced by Edman 
degradation with an Applied Biosystems 494 Procise automated sequencer.  N-terminal 
sequencing was performed by the University of Nebraska Medical Center’s Protein 
Structure Core Facility.   
Chromogenic activity assay 
The chromogenic activity assay was performed using a modified version of the 
procedure described  in Ariëns et al. [39].  A 96-well polystyrene plate (Fisher, Pittsburgh, 
PA) was coated with pd-FI purified by EtOH precipitation (0.04 mg/mL) and then 
blocked with bovine serum albumin (10 mg/mL).  Dilutions of pooled plasma from 10 
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donors (0, 0.0002, 0.0004, 0.0006, 0.0008 and 0.001) were added to some wells and used 
to create a standard curve assuming pd-FXIII content is 1 U/mL. Six dilutions of pure pd-
FXIII (Enzyme Research Labs) and r-FXIIIA1 samples were added to the wells.  Biotin-
pentylamine (Life Technologies) (0.27 µM), dithiothreitol (0.10 mM), CaCl2 (1 mM) and 
r-FIIa (1 U/mL) were added to the wells and incubated at room temperature for 25 min.  
Streptavidin-alkaline phosphatase (Sigma, St. Louis, MO) (2 µg/mL) was added and 
incubated at 37oC for 60 min.  Finally, p-nitrophenyl phosphate (1 mg/mL) in 
diethanolamine (1 M) was added and incubated at room temperature for 2 min.  p-
nitrophenol was detected at 405 nm.  All samples were run in triplicate.  Multiple 
dilutions of pd-FXIII and r-FXIIIA1 that fell within the standard curve range created with 
the plasma dilutions were used to estimate activity.  The mean and standard deviation of 
activity estimates from multiple dilutions are reported. 
FXIIIa catalyzed crosslinking of fibrin 
Crosslinking of pd-FI purified by EtOH precipitation by r-FXIIIA1 was analyzed 
as previously described [41].  pd-FI (0.38 mg/mL) was incubated with and without r-FIIa 
(1 U/mL) and without added FXIII or with pd-FXIII, pd-FXIIIa, or r-FXIIIA1 (1.1 
U/mL) in Ringer’s solution for 0, 1, 2.5, 5, 10 and 15 minutes.  pd-FXIIIa for the trial 
without thrombin was created by treating pd-FXIII with thrombin for 2.5 minutes and 
then inactivating the thrombin in a solution containing 0.02 mM PPACK. Crosslinking 
was examined by reducing SDS-PAGE gel electrophoresis (4-12% Bis-Tris NuPAGE) 
stained with Colloidal Blue (Life Technologies, Carlsbad, CA).  The bands at 
approximately 130 and 150 kDa were excised and the first ten amino acids in the N-
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terminal of each were sequenced by Edman degradation with an Applied Biosystems 494 
Procise automated sequencer [36]. 
Dose Response 
The crosslinking due to dosing of r-FXIIIA1 on r-FI and pd-FI by was analyzed as 
previously described [41].  pd-FI (9mg/mL) and r-FI (9 mg/mL) were incubated in 
Ringer’s solution with FIIa (0.2 mg/mL) and with 0, 0.18, 0.36, and 0.53 mg/mL r-FXIIIa 
to initiate fibrin formation.  The reaction was quenched with LDS and reducing buffer 
after 2.5 minutes. Crosslinking was examined by reducing SDS-PAGE gel 
electrophoresis (4-12% Bis-Tris NuPAGE) stained with Colloidal Blue (Life 
Technologies, Carlsbad, CA). 
Viscoelastic characterization of fibrin crosslinking 
Clot stiffness resulting from fibrin cross-linking of pd-FI by affinity purified  r-
FXIIIA1 was evaluated by thromboelastography (TEG) using a Thromboelastograph® 
(TEG®) Hemostasis System 5000 series (Haemoscope Corp., Niles, IL).  Biotherapeutic 
grade fibrin sealant (Tisseel, Baxter) was formulated according label instructions. Fibrin 
sealant was transferred at 34 mg/mL FI and 9 mg/mL FI, based on a final volume of 360 
μl, into a single-use TEG cup maintained at 37 oC by the instrument. r-FXIIIA1 at a final 
concentration of 2,500 U/mL (0.36 mg/mL) was added to the 9 mg/mL FI samples. CaCl2 
(final concentration: 12 mM) and Ringer’s solution (155 mM  NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, added to standardize volume in cup) were added followed quickly 
by rFIIa (final concentration: 106 U/mL) to initiate fibrin clot formation. Data were 
collected every five seconds for 30 minutes by the TEG interfaced with a computer.  The 
TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected the time to 
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clot initiation (R), the time to achieve a clot firmness of 20mm (K) and the maximum clot 
strength (MA).  The instrument was calibrated each day of use.  Each sample was run in 
triplicate so means and standard deviations could be calculated.  The data was exported 
and analyzed in Microsoft® Excel.   
6.4 Results 
Transgene integration, purification and confirmation of r-FXIIIA1 primary 
structure PCR screening of selected clones of Pichia pastoris were shown to contain 
between one and five gene copies of the expression cassette, containing the dual amino 
and carboxy-terminal His and Myc-tagged r-FXIIIA-chains (Fig. 6.1). In spite of the 
presence of α-secretion signal sequence in cassette, protein was observed to accumulate 
in cell inclusion bodies and not in the culture media after induction of expression.  This 
intracellular protein was extracted and then purified from the cell mass lysate by IMAC. 
The average final yield following the sequence of affinity IMAC purification and post-
elution imidazole elution buffer dilution, dialysis and concentration steps was 
approximately 0.24 mg r-FXIIIA1 antigen per gram cell paste as detected by Western 
analysis. The majority species appearing in the affinity purified product was confirmed to 
be r-FXIIIA1 by comparing Western analysis with stained SDS-PAGE (Fig. 6.2) and 
estimated to be greater than 98% pure. The non-reducing SDS-PAGE analysis of the 
expressed r-FXIIIA1 (Fig. 2A) exhibited an Mr of ~81 kDa and similar to the A-chain of 
reference plasma-derived FXIII sample. Furthermore, this analysis showed that the SDS 
caused the disassembly of the tetrameric pd-FXIIIA reference sample and any multimeric 
structures present in the r-FXIIIA1 preparation.  
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Figure 6.2. Comparison of pd-FXIII and IMAC purified r-FXIIIA1 by SDS-PAGE. Colloidal 
Blue stained SDS-PAGE under (A) non-reducing and (B) reducing conditions; Lane 1. Mr 
marker; Lane 2. pd-FXIII reference; Lane 3. r-FXIIIA1.  Western analysis by (C) polyclonal anti-
FXIIIA and (D) anti-His-tag Mab:  Lane 1. Mr marker; Lane 2. His-tag labeled reference protein 
(APOE), Lane 3. pd-FXIII; Lane 4 r-FXIIIA1. 
 
Surprisingly, amino acid sequencing showed that the N-terminal domain of the r-
FXIIIA1 comprised of the 0.84 kDa His-tag and 1.03 kDa activation peptide was 
removed (Table I).  Western analysis using an anti-His-tag monoclonal antibody 
indicated the presence of the remaining His-tag at the carboxy-terminus of the r-FXIIIA1 
(Fig. 6.2D). Thus, the overall similarity of the Mr of the FXIIIA1 with the pd-FXIIIA-
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chain was consistent with the removal of the activation peptide and remaining presence 
of the carboxy-terminal His-tag used in the IMAC purification.  It is noted that under 
non-reducing conditions, the B-chain from the SDS disassembly of the tetrameric pd-
FXIII reference protein was observed at  Mr  60 kDa, which increased to approximately 
81 kDa under non-reducing conditions (Fig. 6.2B) as previously reported [17]. 
Stokes Radius estimates using SEC 
The Rs  of r-FXIIIA1 in solution was estimated by SEC using a semi-empirical 
correlation [42, 43], originally developed by Laurent and Killander [40].  Four protein 
standards were used to calibrate the constants within the correlation:  the Rs of 6.5 nm 
was used for IgA [44], 5.3 nm for IgG [44],  4.08 nm for coagulation factor IX [45], and 
4.1 nm for Prothrombin [46] where these Rs  were previously determined by analytical 
ultracentrifuge and gel filtration. The resulting linear form of the correlation gave an R2 
of 0.936 using the above reference proteins and the r-FXIIIA1’s retention time yielded an 
Rs of 4.2 nm  (Fig. 6.3C) and Mr of 72 kDa (Fig. 6.3D). The similarity of the Rs of the r-
FXIIIA1 to prothrombin indicates that it predominately occurred as a monomeric form. 
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Figure 6.3. Molecular size and aggregation analysis of r-FXIIIA1 by SEC. (A) Reference protein 
residence time (tr) profiles with MW:  Coagulation factor IX (MW~56 kDa, Rs=4.08 nm, Black), IgG 
(MW~150 kDa, Rs=5.3 nm, green), Prothrombin (MW~72 kDa, Rs=4.1 nm, Gold), and IgA (MW~300 
kDa, Rs=6.5 nm, blue) and r-FXIIIA1 (red).  (B) Magnified SEC profile for r-FXIIIA1 for aggregate 
detection.  (C) Rs prediction using residence time data of panel A and a semi-empirical correlation of  
Laurent and Killander [40] (D) MW prediction using residence time data of panel A. ♦r-FXIIIA1 ■ IgA ● 
IgG ▲ Prothrombin ■ factor IX.  
 
Inactivation of pd-FXIII and r-FXIIIA1 by r-FIIa 
The time course inactivation of pd-FXIIIA2 and r-FXIIIA1 by r-FIIa was 
evaluated by SDS-PAGE gel electrophoresis under reducing conditions (Fig. 6.4).  The 
respective N-terminal sequences of the resulting proteolytic fragments were also 
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determined (Table 6.1). Prior to treatment with r-FIIa, the zymogen pd-FXIII and the r-
FXIIIA1 consisted of single bands at an Mr of approximately 81 kDa (Fig. 4A and B, 
Lane 2).  Within 0.5 min of incubation with r-FIIa, a second band appears for both pd-
FXIII and r-FXIIIA1.  A decrease in Mr of 3 kDa was seen for the pd-FXIII which is 
consistent with the removal of the activation peptide as detected by N-terminal amino 
acid sequencing. In contrast, the r-FXIIIA1 showed an Mr of >3 kDa cleavage where 
approximately half of the r-FXIIIA1 had been proteolyzed by 5 minutes.  Western 
analysis using monoclonal anti-His-tag showed that this cleavage removed the remaining 
carboxy-terminal His-tag.  The total decrease of Mr by >3 kDa indicates that the Myc-tag 
was likely also cleaved. 
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Figure 6.4. Time course r-FIIa proteolysis of pd-FXIII and r-FXIIIA1 by SDS PAGE.  (A) pd-FXIII 
and (C) r-FXIIIA1l treated with r-FIIa for 0 to 5 minutes: Lane 1: molecular weight marker; Lanes 2 
through 9: pd-FXIII or r-FXIIIA1 incubated with r-FIIa for 0, 0.5, 1.0, 1.5, 2, 3, 4 and 5 minutes.  (B) pd-
FXIII and (D) r-FXIIIA1 treated with r-FIIa for 0 to 360 minutes: Lane 1: molecular weight marker; Lanes 
2 through 9: pd-FXIII or r-FXIIIA1 incubated with r-FIIa for 0, 5, 15, 30, 60, 120, 240 and 360 minutes.  
(E) SDS PAGE, (F) Western analysis by monoclonal anti-His-tag, and (G) Western analysis by polyclonal 
anti-FXIIIA of r-FXIIIA1 treated with r-FIIa at 0 and 5 minutes post exposure. Lane 1: molecular weight 
marker; Lanes 2: 0 minutes; Lane 3: 5 minutes; Lane 4: (E, G)  molecular weight marker or (F) His-labeled 
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reference protein (APOE).  The gray arrow indicates the band associated with r-FIIa.  Open and closed 
arrows indicate degradation products at Mr ~25 kDa and ~54 kDa, respectively. 
    
Table 6.1. N-terminal amino acid sequence of purified r-FXIIIA1 and furin cleavage products. 




r-FXIIIIA1 Species Description  
~81 GVNLQEFLNV r-FXIIIA1 + Myc-tag + His-tag 
~79 GVNLQEFLNV r-FXIIIA1 
~54 GVNLQEFLNV r-FXIIIA1 N-terminal-K513 cleavage product 
~25 SRSNVDMXFE r-FXIIIA1 S514-C-terminal cleavage product 
 
While FIIa activates zymogen FXIII, it also further proteolysis FXIIIa to 
inactivate it.  This inactivation of pd-FXIII and r-FXIIIA1 was evaluated by SDS-PAGE 
gel electrophoresis under reducing conditions for six hours (Fig. 4B and 4D).  A-chain of 
the pd-FXIII was noticeably degraded into Mr 25 and Mr 54 kDa fragments by 15 
minutes.  The B-chain of pd-FXIII does not appear to be degraded by r-FIIa.  Similarly, 
the r-FXIIIA1 band, which has no B-chain, also decreases gradually over the incubation 
period with an increase in the Mr 25 kDa band.  In contrast, the appearance of the 
degradation in r-FXIIIA1 was delayed until 30 minutes.  By the end of the 360 minutes, 
very little intact A1 chain remained in either pd-FXIIIA1 or r-FXIIIA1.  The N-terminal 
amino acids of the bands at Mr ~81, ~79, ~54 and ~25 kDa of r-FXIIIA1 were sequenced 
(Table 6.1) and the bands at Mr ~81, ~79,  and ~54 were consistent with that for FXIII 
activated A-chain. The first 10 residues of the 25 kDa band are consistent with the 
thrombin cleavage site at Lys513 [12].   
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Chromogenic activity assay 
The activities of pd-FXIIIa and r-FXIIIA1 were estimated by comparison to 
plasma using a solid phase chromogenic activity assay.  The linear trendline fit to the 
standard curve from plasma had an R2 value of 0.95. Four dilutions of pd-FXIII fell 
within the standard curve yielding a specific activity estimate of 11 ± 6 IU/mg, with IU 
being defined as the amount of FXIII in 1 mL of plasma by Raut et al. [47].  The 
manufacturer provided specific activity of pd-FXIII as 18.9 IU/mg, while literature cites 
normal levels at 11-31 IU/mg in plasma based on a normal range of 10-30 μg FXIII per 
mL plasma  [48, 49].  Two dilutions of r-FXIIIA1 were within the range of the standard 
curve yielding a specific activity estimate of 23 ± 3 U/mg.  Post-hoc analysis (t-test) 
determined that r-FXIIIA1 had significantly greater activity than pd-FXIII (p < 0.025, α = 
0.05). 
The γ-γ crosslinking of fibrin formed from pd-FI by FXIIIa was analyzed by 
SDS-PAGE gel electrophoresis as previously described [41] (Fig. 6.5).  The pd-FXIIIa  in 
the absences of r-FIIa began creating α and γ multimers within 5 minutes, which is 
confirmed by previous literature[50, 51],  while the r-FXIIIA1 in the absences of r-FIIa 
did not catalyze the formation of a significant population until 60 minutes (Fig. 6.5A and 
6.5B).  As previously reported, a constitutive level of FXIII was present in pd-FI 
preparations and was observable by the appearance of γ-γ dimers after treatment by r-FIIa 
alone (Fig. 6.5C). The pd-FI samples containing no added FXIII (Fig. 6.5C) and the 
fibrinogen samples containing pd-FXIII (Fig. 6.5D) catalyzed the formation of γ-chain 
aggregates at similar rates as seen by the disappearance of the γ-chain monomer and 
appearance of the γ-γ dimer.  The rates of γ-chain aggregates of samples containing pd-
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FXIIIa (Fig. 6.5E) and r-FXIIIA1 (Fig. 6.5F) were similar but significantly faster than 
those containing pd-FXIII and no added FXIII.  By the end of the 15-minute incubation 
period, a non-complexed γ-chain band is still visible for the no added FXIII and pd-FXIII 
samples.  The γ-chain band for the pd-FXIIIa and r-FXIIIA1 samples is essentially gone.  
The α-chain monomer is also disappearing for all samples resulting in higher molecular 
weight bands.  The α-chain of samples with no added FXIII, pd-FXIII and pd-FXIIIa 
decreases at a similar rate but a majority remains after 15 -minutes of incubation.  
However, the α-chain of the r-FXIIIA1 sample gradually decreased, leaving very little 
monomer remaining at the end of the 15-minute incubation period.  N-terminal 
sequencing indicates the presence of both α- and γ-chain multimers in all samples.     
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Figure 6.5. SDS-Page of fibrin crosslinking by r-FXIIIA1 versus zymogen pd-FXIII.   Purified pd-FI 
(0.38 mg/mL) having a typical constitutive level of FXIII activity was treated with and without r-FIIa (1 
U/mL) to initiate fibrin formation in the absence and presence of added zymogen pd-FXIII or pd-FXIIIa 
having prior activation by FIIa or r-FXIIIA1 (1.1 U/mL): (A) no r-FIIa with added pd-FXIIIa (B) no r-FIIa 
with added r-FXIIIA1; (C) r-FIIa alone; (D) r-FIIa with pd-FXIII; (E) r-FIIa with pd-FXIIIa; (F) r-FIIa with 
r-FXIIIA1.  All samples run under reducing conditions. All panels Lane 1: molecular weight marker; Lane 
2: pd-FI prior to r-FIIa and FXIII treatment; Lanes 3 through 8: pd- FI, r-FIIa and FXIII incubated for 0, 1, 
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2.5, 5, 10 and 15 minutes.  Panel A only:  Lane 9: pd-FI, r-FIIa and FXIII incubated for 60 minutes; Lane 9 
r-FXIIIA1; Panel B only:  Lane 9 r-FXIIIA1; Lane 10: pd-FI, r-FIIa and FXIII incubated for 60 minutes. 
The Aα-, Bβ- and γ-chains (66, 52 and 46 kDa, respectively) of FI are indicated by α, β, and γ, γ- γ 
indicates the cross-linked γ-chains.  The gray arrow indicates the band associated with the added FXIII 
species.  As detected by N-terminal sequencing, the open arrow indicates an α-chain multimer and the 
closed arrow indicates a γ-chain multimer. 
 
Dose Response 
The dose response crosslinking of both r-FI and pd-FI to r-FXIIIA1 and r-FIIa 
were evaluated by SDS-PAGE (Fig. 6.6).  The reaction of r-FXIIIA1, FI, and r-FIIa was 
allowed to continue for 2.5 minutes before being quenched by LDS and reducing buffer. 
No γ-γ dimer was found in the r-FI sample in the absence of r-FXIIIa, while pd-FI 
produced a noticeable amount of γ-γ dimer in the absence of non-endogenous r-FXIIIA1.  
When dosed with r-FXIIIA1, both samples produced α- and γ-chain multimers in addition 
to γ-γ dimer in a dose-dependent manner. 
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Figure 6.6. Dose-response SDS-Page of r-FXIIIA1 on r-FI with no endogenous FXIII and pd-FI 
containing endogenous FXIII. (A) pd-FI (9mg/mL) and (B) r-FI (9 mg/mL) were incubated with FIIa (0.2 
mg/mL) and with and without r-FXIIIa to initiate fibrin formation.  The reaction was quenched with LDS 
and reducing buffer after 2.5 minutes.  Lane 1: Molecular weight marker; Lane 2: No added r-FXIIIA1; 
Lane 3: 0.18 mg/mL r-FXIII added; Lane 4: 0.36 mg/mL r-FXIII added; Lane 5: 0.53 mg/mL r-FXIII 
added. The Aα-, Bβ- and γ-chains (66, 52 and 46 kDa, respectively) of FI are indicated by α, β, and γ, γ-γ 
indicates the cross-linked γ-chains.  The gray arrow indicates the band associated with the added FXIII 
species.  As detected by N-terminal sequencing, the open arrow indicates an α-chain multimer and the 
closed arrow indicates a γ-chain multimer. 
 
Viscoelastic properties  
The effectiveness of r-FXIIIA1 in increasing clot strength of pd-FI was evaluated 
by thromboelastography (TEG) (Fig. 6.7).  The evolution of viscoelasticity during the 
formation of a crosslinked fibrin clot from 34 mg/mL FI biotherapeutic fibrin sealant was 
measured against 9 mg/mL FI biotherapeutic fibrin sealant with 0.36 mg/mL r-FXIIIA1. 
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The lower concentration of fibrin sealant with r-FXIIIA1 was found to reach a maximum 
amplitude plateau over 6 minutes before higher concentration fibrin sealant without any 
added FXIII while maintaining significantly higher maximum amplitude for over 15 
minutes. 
 
Figure 6.7. Thromboelastography acceleration and strengthening of plasma-derived biotherapeutic 
grade fibrin sealant by rFXIIIA1. TEG analysis of the kinetics of clot initiation and clot strength over 
time for biotherapeutic grade fibrin sealant at 33.5 mg/mL ( ) and biotherapeutic grade fibrin sealant 




The expression cassette used here to produce FXIIIA1 contained an alpha 
secretion signal as well as N- and COOH-terminal affinity tags that flanked the primary 
sequence of the A-chain.  In spite of the secretion signal, the cell media showed almost 
undetectable levels of A-chain antigen while the FXIIIA-chain was easily purified by 
IMAC from cell lysates at 0.24 mg per gram cell paste. Surprisingly, it had been 
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converted into a FXIIIA1 without the amino-terminal activation peptide.  This r-FXIIIA1 
demonstrated high specific activity and contained no other degradation.  While the 
activation resulted in the loss of the N-terminal His tag, it left the carboxy-terminal His 
tag still in place which enabled IMAC purification.  In summary, a prodigious yield from 
cell lysates was obtained showing the capacity of the P. pastoris to intracellularly process 
r-FXIIIA1 into r-FXIIIA1 without an amino-terminal activation peptide.   
While the specificity of the intracellular activation of the A-chain is indicative of 
a serine protease with thrombin-like activity, we found that further treatment with human 
thrombin resulted in the cleavage of the carboxy-terminal His affinity tag sequence. A 
time course loss of the anti-His Mab signal was observed over 5 minutes with a 
concomitant reduction in Mr of about 3 kDa while retaining the N-terminal sequencing 
FXIIIA1.  We could not verify the carboxy-terminal removal of the Myc affinity tag that 
was juxtaposed between the FXIIIA1 and the carboxy terminal His tag, as we could not 
obtain a myc-tag antigen signal before or after thrombin treatment.   At longer times,  we 
observed further proteolysis by thrombin to inactivate the FXIIIA1 with similar cleavages 
than that observed with the activated A-chain of pdFXIIIA2 [17] yielding fragments of 
approximately 25 and 54 kDa.  The physiologic feedback inactivation of FXIIIA2a by 
thrombin exerts an important control over fibrin cross-linking.    
Although the primary structure of r-FXIIIA1 appears similar to pd-FXIIIA2a 
produced from activating pdFXIII, the quaternary structure is different.  Past studies of 
zymogen pd-FXIIIA2 from platelets and r-FXIIIA2 from S. cerevisiae and also their 
respective thrombin activated products have been reported to be homodimeric structures 
[30].   In contrast, we observed by HPSEC analysis that the r-FXIIIA1 purified here from 
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P. pastoris primarily exists as a monomer with only small amounts of aggregates.  It is 
possible that the intracellular activation and or carboxy-terminal His tag could prevent the 
dimer formation.  We estimate the specific activity of the r-FXIIIA1 to be >2-fold higher 
than pd-FXIIIA2a. Despite possible differences in quaternary structure, inactivation of r-
FXIIIA1 by thrombin was similar if not slightly slower than its plasma-derived 
counterpart.  These results were similar to those seen with r-FXIIIA2 produced in 
Saccharomyces cerevisiae that has been advanced to human clinical study [52, 53].   
We used r-FXIIIA1 to assess the nature and kinetic benefit of the cross-linking of 
fibrin made when augmenting the pd-FXIII activity that is constitutively present in most 
pd-FI preparations [54]. This constitutive activity arises from pd-FXIII that is associated 
with the γγ’ heterodimer subpopulation, which is about 20% of the total pd-FI population 
[1, 35, 55].   The r-FXIIIA1 catalyzed a similar distribution of cross-linked fibrin 
products to that from pd-FXIII:  both γ-γ chain cross-linked dimers and higher molecular 
weight fibrin cross-linking involving the α-chains were made from thrombin treated pd-
FI (Fig. 6.5). The  α-α fibrin crosslinking  is especially important for overall clot strength 
[6].   With respect to crosslinking kinetics, we observed an appreciable lag in the onset of 
fibrin crosslinking kinetics of pd-FI having only constitutive pd-FXIII zymogen, relative 
to those when the fibrin formation was in the presence of augmented levels of r-FXIIIA1 
or pd-FXIII2Aa.  The pd-FI samples treated by pre-activated pd-FXIII and r-FXIIIA1 
treatment groups yielded much faster γ-γ and α-α crosslinks.  This relative lag is likely 
due to the activation step by thrombin on the constitutively present pd-FXIII.   
Interestingly, the r-FXIIIA1 appears to have a longer crosslinking lag-time than 
pd-FXIIIa when there is no thrombin present.  As Fig. 6.5B demonstrates, r-FXIIIA1 is 
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not sufficient to induce the creation of α and γ multimers in a kinetically favorable time.  
However, in the presence of r-FIIa, r-FXIIIA1 produces α and γ multimers in a 
kinetically favorable manner that is similar to pd-FXIIIa.  The slower formation of  α and 
γ multimers in the absence of thrombin and the kinetically favorable formation of these 
same multimers in the presence of thrombin indicates the creation of an artificial, 
kinetically favorable activation peptide in the form of the carboxy-terminal His- and myc-
tag.  The activation times for pd-FXIII and r-FXIIIA1 as seen in Fig. 4A and 4C 
correspond to the  lag time in the creation of α and γ multimers in Fig. 5B and 5C. 
Today’s surgical sealants rely solely on the constitutively present FXIII for fibrin 
cross-linking and thus consist of only thrombin and pdF1 starting materials.  The addition 
of rFXIIIA1 would eliminate the 2 minute lag in cross-linking and decrease the time for a 
clot to reach maximum strength by over 15 minutes. The r-FXIIIA1 could be added at an 
optimized dose to potentially improve topical fibrin sealants in treatment of acute 
hemorrhage.  We have previously investigated the use of r-FXIIIA1 in recombinant 
sealants [37]. 
We have produced a functional r-FXIIIA1 in abundance in Pichia pastoris.  The 
production of r-FXIIIA1 rather than FXIIIA2 may be beneficial for therapeutic uses.  The 
use of rFXIIIA1 in topical sealants creates a kinetically favorable time-lag compared to 
the activation of tetrameric, BB/AA structure of the pd-FXIII zymogen, which proceeds 
through a step that dissociated of the B-chain [22-26] and also the removal of the 
activation peptide.  Importantly, in the absence of thrombin, the rFXIIIA1 showed a 
greatly reduced cross-linking activity related to the removal of the His- and myc-tag 
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Chapter 7:         
Thromboelastic Kinetics are Increased by Recombinant Human Factor XIII 
Nicholas Vanderslice*, Jennifer Calcaterra*, Ayman Ismail*, Mehmet Inan,* Vijay P. 
Jain,* William H.Velander* 




Background: Factor XIII (FXIII) is activated by thrombin (IIa) during fibrin formation 
releasing a dimeric, transglutaminase which both converts fibrin into a crosslinked, 
viscoelastic barrier and also covalently anchors to wound surfaces.  The dose-dependent 
clot kinetics of coagulation factors during fibrin clot formation and strengthening are not 
yet understood. Thromboelastography (TEG) is a common method for determining these 
initiation time and strength of a clot; however, the influence of the transport phenomena 
associated with TEG, especially in the case of fibrin sealants, is not well characterized in 
literature.  
Methods:  Normal human blood, platelet poor plasma, platelet rich plasma, and fibrin 
sealant were assayed by thromboelastography (TEG) to assess the effect of crosslinking 
on clot strength and initiation time. Fibrin sealant (FS) containing recombinant thrombin, 
recombinant fibrinogen, and recombinant FXIII was also doped into the human blood 
products to assess the effect of elevated clotting factors for potential topical use.   
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Results: Thromboelastic behavior of fibrin formation was assessed for pdF1 
concentrations typical of plasma at 9 mg/mL to that of FS at 34 mg/mL. It took 1000 
seconds for tissue sealant to reach an MA=75 mm without rFXIIIa1a treatment while a 
0.16 molar ratio of rFXIIIA1a to pd-F1 took only 450 seconds to reach an MA=75 mm 
while at only 9 g/mL pd-F1.  Thromboelastic behavior was found to exhibit vastly 
different transport models based on the concentration of platelets and coagulation factors.  
At low levels of platelets or fibrinogen, the volume of the clot is insufficient to establish 
the standard transport regime where the clot is in contact with both wall of the TEG cup.  
The inability of the clot to contact both walls of the TEG cup vastly changes the 
rheological properties measured by TEG.   
Conclusions: The levels of coagulation factors and platelets have the potential to change 
rheological factors measured by TEG due to changes in the solid and liquid interfaces. 
These findings have a profound implications for the measurement of the effects of 
coagulation factors like factor XIII which crosslink and compact the clot. 
 
7.2 Introduction 
The coagulation cascade is responsible for restoring hemostasis in the event of an 
injury [1, 2].  This convoluted mechanism contains over 15 different proteins including 
serine proteases, transglutaminases, and glycoproteins.  The end result of the coagulation 
cascade is a fibrin clot that holds together platelets in a mesh that prevents further blood 
loss [3].  However in many instances of traumatic hemorrhage, the rate of blood loss 
exceeds the capabilities of the body to both maintain levels of coagulation factors and/or 
form a clot with substantial strength to restore hemostasis [4].  In order to restore 
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hemostasis in these cases, liquid fibrin sealant (FS) containing fibrinogen (Fib), a 340 
kDa glycoprotein responsible for holding a clot together, calcium, and thrombin (IIa), a 
serine protease responsible for activating Fib and several other coagulation factors [1, 5-
7].  Factor XIII (FXIII), a transglutaminase responsible for crosslinking Fib, has also 
previously been looked at as an additional protein for its clot strengthening properties [8]. 
Traditionally plasma-derived proteins have been used in FS due to their availability, but 
the growing availability of recombinant proteins has allowed the creation of a wholly 
recombinant FS that is currently in preclinical trials [4]. 
The traditional assays for clot kinetics and strength are thromboelastography 
(TEG) and rotational thromboelastometry (ROTEM) [9].  These assays rely on 
perturbation of the clot to measure the adhesion and strength of the clot at 37° C, and 
have the advantage of being accurate enough for laboratory use while also swift enough 
to provide results in the surgical theater [10]. TEG functions by rotating a 360 μl TEG 
cup around a torsion wire connected to a pin suspended in a coagulating solution  and 
measuring resistance as the clot forms around the pin [11]. ROTEM in contrast rotates 
the pin and measuring the resistance through either optical or torsion sensors.  By 
measuring this increase in resistance, four clotting variables can be found: maximum 
amplitude (MA), a measure of the maximum resistance and clot strength reached; 
reaction time (R), the time until clotting is first detected; K value (K), the time from R 
until the clot is fully formed, indicated by an amplitude of 20 mm; and angle (α), the 
tangent of the K. Values for K and α are not considered valid unless the clot reaches a 
strength of 25 mm.  These variables can be taken together to find information about clot 
kinetics and strength.  This information is valuable to both scientists evaluating the 
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strength of FS and surgeons evaluating the presence of coagulation factors during a 
surgery. This chapter strives to characterize the effect of the components of FS both as an 
isolated combination of proteins and in the presence of blood products that would be seen 
in application.  
 
7.3 Materials and Methods 
Materials 
Purified, plasma-derived prothrombin was bought from Enzyme Research 
Laboratories (South Bend, IN). Recombinant thrombin (Recothrom®) was purchased 
from Zymogenetics.  Purified plasma-derived fibrinogen was purchased from Enzyme 
Research Laboratories or purified on-site from donated blood.  Purified recombinant 
fibrinogen (rFib), expressed in the milk of transgenic Swiss Brown cows, was obtained 
from Pharming Group NV (Leiden, Netherlands). Thromboelastography materials were 
purchased from Haemoscope (Niles, IL). Recombinant FXIII was obtained from Pichia 
pastoris using methods described in Chapter 6.  Unless otherwise specified, reagents 
were purchased from Sigma (St. Louis, MO). 
Thrombin preparation 
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories, 
South Bend, IN), was thawed at 37oC. Plasma-derived thrombin (Enzyme Research 
Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin 
ratio. 0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin 1965). 
This solution was incubated at 37oC on a rotating mixer for five hours. Sodium citrate 
was removed using PD-10 desalting columns (GE Healthcare, Giles, United Kingdom). 
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Activation of prothrombin to thrombin was confirmed by reducing and nonreducing 
SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained with Colloidal 
Blue (Invitrogen, Carlsbad, CA). The concentration of the thrombin solution was 
determined by standard Bicinconic Acid (BCA) methods. The specific activity was 
determined by one-stage coagulation assay. 
Human blood sampling and processing 
Fresh, normal whole human blood (NHB) from 20 healthy, medication-free 
individuals, collected in tubes containing 3.2% citrate, was obtained from Research 
Blood Components (Brighton, MA). Each individual NHB sample was divided into 
thirds. The NHB sample remained unprocessed while the other two were processed into 
platelet rich plasma (PRP) and platelet-poor plasma (PPP). PRP was prepared by 
centrifuging NHB at 160xg for 8 minutes at 22oC. NHB was centrifuged at 2300xg for 15 
minutes at 22oC to obtain PPP. All blood fractions were used within 36 hours of being 
drawn and were stored at 0oC until analyzed at which time the samples were warmed to 
37oC. 
Thromboelastography analysis of fibrin clot formation 
TEG analysis was conducted on individual fresh, citrated NHB, and respectively 
derived PRP and PPP samples from 20 individuals. Aliquots of each NHB, PRP and PPP 
sample were dosed with purified rFib, FXIII and/or IIa alone or in combination. All blood 
fractions were diluted to 1.3x to provide volume for addition of the biologics. Control 
samples were performed to determine the effects of diluting NHB, PRP and PPP based on 
time to clot initiation (R), coagulation time (K, time to reach clot firmness of 20 mm) and 
maximal clot strength (MA) as evaluated by TEG. Each NHB and respective plasma 
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sample (429.72 μl) was transferred to single-use TEG cups that had been enlarged by 
boring with a 0.406 inch bit (650 μl final volume). Combinations of solutions containing 
rFib (1.42 mg, 2.32 mg/mL rFib in cup), FXIII (0.11 mg, 0.18 mg/mL FXIIIa in cup, 
FXIII/rFib molar ratio = 0.16), IIa (0.08 mg, 0.13 mg/mL IIa in cup, IIa/rFib molar ratio 
= 0.25), and CaCl2 (11 mM) were added to the TEG cups. Ringer’s solution was used to 
normalize mixture volumes. 
 The TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected R, 
K, α, and MA for blood products collected from 20 donors. Samples were run until 
program termination.  The instrument was calibrated each day of use. All tests described 
above include three replicate samples in each treatment group. All NHB and respective 
plasma samples were tested within 36 hours of the blood draw of each individual donor. 
NHB, PRP and PPP samples from 20 donors were tested untreated and treated with rFib 
alone, rFib and IIa together, rFib and FXIII together, rFib, FXIII and IIa together. NHB, 
PRP and PPP samples from 10 donors were tested when treated with IIa alone, FXIII 
alone and IIa and FXIII in combination. 
Thromboelastography of Fibrin Sealant 
Samples of FS were also analyzed using 360 μl TEG cups.  All assays were 
carried out at 11 mM calcium and all assays with exogenous FXIII and IIa contained a 
FXIII to Fib molar ratio of 0.16 and a IIa to Fib molar ratio of 0.25.  Biotherapeutic grade 
FS (Tisseel®, Baxter) was analyzed at 3 mg/mL without FXIII and IIa, formulation 
strength (minimum of 34 mg/mL Fib) without FXIII and IIa, 3 mg/mL Fib in the 
presence of FXIII, and IIa and at 9 mg/mL Fib in the presence of FXIII and IIa. Plasma-
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derived fibrinogen (pdFib) and rFib were analyzed at 9 mg/mL with and without IIa and 
FXIII. 
Optical Imaging 
 Images of NHB, PRP, PPP, and PS in TEG cups were obtained post-termination 
of the TEG run.  Images of the TEG cup before, during, and after removal of the pin were 
taken using a Canon Powershot®.  FS at 3, 4.35, and 9 mg/mL pdFib, a FXIII to Fib 
molar ratio of 0.16, and a IIa to Fib molar ratio of 0.25 were imaged.  NHB was dosed to 
a final FS concentration of 3, 4.35, and 5 mg/mL pdFib, PPP was dosed to a final FS 
concentration of 3 and 5 mg/mL, and PRP was dosed to final FS concentration of 3 
mg/mL, all at the same molar ratio of FXIII and IIa previously stated.  Samples were 




Addition of Coagulation Factors to Normal Human Blood Products 
 Samples of NHB, PRP, and PPP exhibited a wide range of variance in both clot 
initiation time and overall clot strength (Fig 7.1).  This variance is attributed to the 
difference between human donors’ level of coagulation factors.  Overall, NHB, PRP, and 
PPP exhibited similar clot initiation time medians and ranges, but exhibited stark 
differences in maximum amplitude.  Due to the increased platelet count and coagulation 
factors found in the PRP fraction, PRP exhibited a marked increase in median clot 
strength while PPP exhibited a significant reduction.  The addition of FXIII and IIa had 
either no effect on the median sample clot strengths or reduced the clot strength; 
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however, increased exogenous FXIII alone was able to decrease clot initiation time and 
the addition of IIa greatly reduced clot initiation time by over ten-fold. The addition of 
rFib to the human blood products and FXIII increased the median clot initiation time, but 
the addition of IIa brought the clot initiation time back to levels similar to samples with 




Figure 7.1.  Median clot strength (MA) and clot formation time (R) as a function of FXIII, rFib, and 
IIa.  Normal Human Blood (■) Platelet Rich Plasma (■) Platelet Poor Plasma (■). Data are plotted as 
median and the maximum and minimum detected values are indicated by the error bars (N=20). 
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 The mean values of this same study with outliers removed reveal several 
additional pieces of information.  The data shows an increase in clot strength in the 
presence of rFib for all human blood products.  FXIII had no significant impact on the 
clot strength of NHB and PRP in the absence of IIa, but increased the average clot 
strength of PPP significantly.  Interestingly, FXIII with IIa reduced overall clot strength 
and greatly reduced the clot initiation time in all human blood products.  In contrast, the 
clot formation time for PRP and NHB appeared to increase in the presence of IIa.  These 
results were analyzed again as total clot formation time, the sum of clot initiation time 
and clot formation time (Fig. 7.3).  It was found that in NHB, a significant change in total 
clot formation time was not seen unless all three exogenous coagulation factors were 
increased, while in PRP, a decrease was seen with the addition of exogenous FXIII, FXIII 






Figure 7.2. Mean clot strength (MA), clot formation time (R), and two TEG rheological variables (K 
and α) as a function of FXIII, rFib, and IIa.  Normal Human Blood (■) Fibrin Sealant formulated at 4.35 
mg/mL FI (■) Platelet Rich Plasma (■) Platelet Poor Plasma (■). Data are plotted as mean ± SEM (N=20).
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Figure 7.3. Time from assay initiation to clot firmness equaling an amplitude of 20 mm. Normal 
Human Blood (■) Platelet Rich Plasma (■) Platelet Poor Plasma (■). Data are plotted as mean ± SEM 
(N=20).  Samples which did not reach a maximum amplitude of 25 mm were excluded from this analysis.
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 In contrast to the FS in the presence of human blood products, FS containing 
FXIII exhibited a significant increase in clotting strength for both rFib and pdFib (Fig. 
7.4A). rFib exhibited a lower clot strength than pdFib; however, in the presence of FXIII 
nearly equaled the clot strength of pdFib.  In the case of a commercial FS, the addition of 
FXIII at FXIII to Fib molar ratio of 0.16 to commercial biotherapeutic FS formulated 9 
mg/mL resulted in the same maximum amplitude as commercial FS formulated at a 
minimum of 34 mg/mL Fib.  In addition, the maximum amplitude of the sample 
containing 9 mg/mL Fib was reached in 450 seconds, significantly less than the label 
strength FS which took 1000 seconds to reach the same clot strength.  However, when 
commercial biotherapeutic FS was formulated at 3 mg/mL, the addition of FXIII 
exhibited reduced clotting strength with identical clot kinetics, indicating a lower 
threshold for this effect. 
 Upon examining the TEG cups after successful completion of the experiments, 
several different morphologies were seen (Fig 7.5-7.8).  All images without removed pins 
shown indicate that no clot was attached to the pin.  The 3 mg/mL Fib FS and PPP 
exhibited limited solidification and almost no attachment to the pin.  Higher 
concentrations of FS exhibited weak attachment to the pin and strong attachment to the 
outer wall.  The gap between the clot attached to the outer wall of the TEG cup and the 
pin was reduced as FS concentration increased.  In NHB dosed with FS, PRP with and 
without added FS, and PPP with 5 mg/mL FS added, the clot attached to the pin and 
could be removed from the TEG cup with the clot still attached.  These samples had the 
smallest liquid gaps between the clot and the walls of the TEG cup and often 
demonstrated attachment to the outer wall upon removal of the pin. 
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Figure 7.4.Viscoelastic characterization of pdFib and rFib treated with IIa with and without added 
FXIII.   A) TEG analysis of the kinetics of clot initiation and clot strength over time for 9 mg/mL pdFI 
activated by rFIIa without added FXIII (●), 9 mg/mL pdFI activated by IIa with added FXIII (▲), 9 mg/mL 
rFib activated by IIa without added FXIII (■), and 9 mg/mL rFib activated by IIa with added FXIII ( ).  
Data are expressed as mean  ± standard deviation. B) TEG analysis of the kinetics of clot initiation and clot 
strength over time for 34 mg/mL biotherapeutic grade FS without exogenous FXIII ( ) and 9 mg/mL 
biotherapeutic grade FS with added FXIII ( ). C) TEG analysis of the kinetics of clot initiation and clot 
strength over time for 3 mg/mL biotherapeutic grade FS without exogenous FXIII ( ) and 3 mg/mL 
biotherapeutic grade FS with added FXIII ( ).  
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7.5 Normal TEG morphology for normal human blood products.  A) In NHB, the clot formed 
alongside the outer wall with a small liquid gap between the clot and the pin; B) In PRP, the clot formed 
alongside the pin with a medium liquid gap between the outer wall and the clot; C) In PPP, the clot formed 
as a mixture that did not attach to the TEG cup.  
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Figure 7.6. Changes in TEG transport model based on concentrations of fibrin sealant coagulation 
factors. A) At 3 mg/mL pdFib FS, a thin layer of sealant attached to the outer wall of TEG cup with a large 
liquid gap between the pin and the FS; B) At 4.35 mg/mL pdFib FS, a medium layer of sealant attached to 
the outer wall of TEG cup with a small liquid gap between the pin and the FS; C) At 9 mg/mL pdFib FS, a 
large layer of sealant attached to the outer wall with no liquid gap between the walls and the FS. 
153 
  
Figure 7.7. Changes in TEG transport model based on concentrations of fibrin sealant coagulation 
factors added to Normal Human Blood.  A) In NHB with 3 mg/mL pdFib FS added, a medium layer of 
clot attached to the pin of TEG cup with a medium liquid gap between the outer wall and the clot; B) In 
NHB with 4.35 mg/mL pdFib FS added, a medium layer of clot attached to the pin of TEG cup with a small 
liquid gap between the outer wall and the clot; C) In NHB with  9 mg/mL pdFib FS added, a larger layer of 
clot attached to the outer wall with a minimal liquid gap between  the walls and the clot. 
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Figure 7.8. Changes in TEG transport model based on concentrations of fibrin sealant coagulation 
factors added to PRP and PPP.  In PPP with 3 mg/mL pdFib FS added, a medium layer of clot attached 
to the outer wall of TEG cup with a medium liquid gap between the pin and the clot; B) In PPP with 5 
mg/mL pdFib FS added, a larger layer of clot attached to the pin of TEG cup with a small liquid gap 
between the outer wall and the clot; C) In PRP with 3 mg/mL pdFib FS added, a larger layer of clot 
attached to the pin with a minimal liquid gap between clot and the walls of the TEG cup. 
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7.5 Discussion 
We have demonstrated that at least four different morphologies can occur during 
TEG: a non-solidified clot which does not attach to the TEG cup, a clot which attaches to 
the outer wall of the TEG cup leaving a liquid gap between the clot and pin, a clot which 
attaches to the pin of the TEG cup leaving a liquid gap between the clot and outer wall, 
and a clot which attaches to both the pin and outer wall.  While technical limitations 
prevent us from observing the TEG while running, these post-experimentation 
observation allow us to draw some qualitative conclusions.  The location of the 
attachment of the clot plays a large role in the modeling of the strength and clot 
formation.  If the clot attaches to the outer wall and is insufficient in size to attach to the 
pin, the TEG will measure a different phenomenon than a clot that attaches to a both 
walls.  Transport phenomenon shows the profound differences in the cases of annulus 
where the inner and outer ring are rotating [12], and the addition of multiple, shearing 
layers of expanding and contracting clot only expands the complexity of modeling these 
scenarios.  While TEG provides accurate and robust data for the cases of attachment of 
the clot to both walls, the accuracy of the device for low concentrations of platelets and 
fibrinogen must be re-evaluated. 
The differences in impact of FXIII on maximum clot strength can be explained by 
the compaction of the clot by platelet borne and exogenous FXIII.  Previous studies have 
shown both ex vivo and in vivo that blood without FXIII exhibits larger clots with lower 
strength [13-16].  From this it can be hypothesized that the reduced clot size of samples 
containing FXIII directly impacts the likelihood of attachment to both the pin and outer 
wall of the TEG cup.  As resistance of the torsion wire used to detect increased clot 
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strength depends on attachment to both walls, the effect of FXIII on clot strength may 
need to be re-evaluated using a methodology that can account for decreased clot size. 
The total clotting time also indicates a profound resiliency of coagulation cascade 
to modification.  Samples of NHB with added coagulation factors exhibited largely 
unchanged total clotting time unless additional IIa, FXIII, and Fib were all present.  In 
PRP, a subpopulation with increased concentration of coagulation factors bound to 
platelets [17, 18], the addition of FXIII and IIa appear to accelerate total clot formation.  
rFib and FXIII without additional IIa introduces new kinetic lag.  While new 
experimental methodology is necessary to determine the exact kinetics of the human 
blood products with and without additional coagulation factors due to both clot 
compaction and the natural variance between humans, these results present preliminary 
indications of the effects of IIa, FXIII, pdFib, and rFib on clot kinetics and strength. 
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8.1 Abstract 
 Fibrinogen, factor XIII, and thrombin are three coagulation factors that can be 
used to create a liquid fibrin sealant (FS) capable of regaining hemostasis in the case of 
uncontrolled bleeding. Several novel prototype systems have been designed to apply FS 
derived from recombinant and human plasma sources. A porcine hepatic resection model 
was developed as a tool to study FS hemostatic devices. Several prototype applications 
platforms were designed to deliver FS to the wound site. These device designs include: a 
spray device capable of delivering a mist of FS to the wound site, a biodegradable 
electrospun polymer gauze treated with FS before application to the liver, and a carrier 
foam device capable of creating an abdominal tamponade effect while delivering FS to 
the site of the injury. Including control surgeries, over 200 combined swine surgeries 
have been performed to date using these devices.  Together these devices provide a suite 
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of applications that have potential medical uses for applying fibrin sealant in both 
emergency and surgical applications. 
 
8.2 Introduction 
Liquid fibrin sealant (FS) has been commercially available since the 1970s [1] for 
treatment of  severe hemorrhage.  Containing fibrinogen (FI) [2-4], thrombin (FIIa) [5, 
6], and occasionally factor XII (FXIII) [7, 8], FS forms a thick fibrin gel that is capable of 
adhering to a wound site and ceasing blood loss [9-12].  However, several technical and 
economic issues have limited the number of applications for FS.  Foremost of these 
issues is the prohibitive cost of plasma-derived coagulation factors.  The cost of these 
factors depends on the availability of donor blood [13], a commodity in notoriously high-
demand.   
The recent advent of recombinant technology provides an alternative avenue for 
approaching the supply of coagulation factors, but due to the high complexity of most 
coagulation factors, mammalian cells are required to produce most coagulation serine 
proteases and glycoproteins [2, 9, 14].  Concomitant to this is the large amount of 
materials needed to ensure that the FS is not carried away from the wound site by the 
blood loss.  Due to both of these issues, the US defense department has sponsored various 
programs to develop devices that can economically be used to treat combat injuries [15, 
16]. 
Current delivery devices rely on either a disposable dual syringe (Duploject, 
Baxter) (Fig. 8.1A) or aerosolization (PTI) to deliver FI and FII independently to the 
wound site without significantly clogging the device.   We have previously published 
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information on a modified, preclinical dual-syringe designed to deliver FS without 
developing a clot in the syringe (Fig 8.1B) [9, 17] and previous dissertations [18] have 
described a spray device designed to deliver FS directly to the wound site (Fig. 8.1C) and 
a bioabsorbable propriety electrospun poly(D,L-lactide) (PLA) polymer (Fig. 8.1D) 
designed to be coated with FS and provide a scaffold that ensures the FS is applied 
directly to the wound site with limited washing away of the coagulation factors.  This 
chapter is designed to show the progress made in designing a robust FS delivery device 
capable of treating severe hemorrhaging.  
 
Figure 8.1. Fibrin sealant devices used for swine surgeries.  Proprietary dual-chamber syringe device 
(Duploject, Baxter) for administration of the commercial FS [2]. (B) Improvised double syringe assembly 
for administration of FS [2]. (C) Dual-airbrush FS device designed to mix fibrin sealant as a mist in 
transport (D) Perforated, corrugated PLA bandage. (E) Device designed to coat carrier foam with FS. (E) 
Multi-channel device designed to coat carrier foam with FS. (G) Front of multi-channel device. Large 
channels are designed to carry highly viscous fibrinogen at the same rate as the low viscosity thrombin and 
factor XIII in the smaller channels.    
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8.3 Materials and Methods 
Materials 
Recombinant thrombin (Recothrom®) was purchased from Zymogenetics.  
Purified plasma-derived fibrinogen was purchased from Enzyme Research Laboratories 
or purified from donated blood.  Purified recombinant fibrinogen (rFI), expressed in the 
milk of transgenic Swiss Brown cows, was obtained from Pharming Group NV (Leiden, 
Netherlands). Recombinant FXIII was obtained from Pichia pastoris using methods 
described in Chapter 6.  Unless otherwise specified, reagents were purchased from Sigma 
(St. Louis, MO). Shaving cream (Barbasol) or proprietary butane propelled alginate foam 
(LNK Chemsolutions) was used as FS carrier foam for these studies. FS was applied at 9 
mg/mL FI, 0.36 mg/mL FXIII, and 0.18 mg/mL FII.  These levels were previously 
determined to be optimal for maximum clot strength and minimum clot formation time 
[9, 18]. 
Swine Studies 
 Surgeries were conducted on crossbred commercial (domestic) swine from UNL 
Agricultural Research and Development Center (Mead).  The Omaha Veteran’s Affairs 
Institutional Animal Care and Use Committee approved all procedures.  All animals were 
treated according to the Guide for the Care and Use of Laboratory Animals (National 
Institute of Health publication 86-23, revised 1996). 
 The abdominal cavity of the anesthetized swine was opened prior to hepatic 
resection.  A splenectomy was performed on the animal to allow for exsanguination 
similar to humans to occur after hepatic resection.  The portal and hepatic veins of the left 
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lateral lobe of the animals were transected and allowed to bleed for 30 seconds before 
administration of FS-coated carrier foam.  Hemostats were used to seal the abdominal 
cavity and pressure was allowed to build inside the cavity.  Animals were observed for 1 
hour or 3 hours unless exsanguination occurred prior to this time.  Animals surviving the 
observation period were euthanized and a post-mortem analysis was conducted on the 
liver for presence of clot at the site of the injury and to ensure transection of the portal 
and hepatic veins.  The atriums of the heart were also opened to detect the presence of 
clot or foam inside. 
Liquid Fibrin Sealant Coated Carrier Foam Device  
 An annulus device was designed to deliver FS coated carrier foam to the 
abdominal cavity of the swine (Fig. 8.1E).  This device contained a large inner tube for 
delivery of carrier foam, and was surrounded by an isolated outer ring that delivers the FS 
around the foam.  The device used the 28 mL delivery system described in a previous 
dissertation [18].  This system was designed to simultaneously deliver a 14 mL mixture 
of fibrinogen and Ringer’s solution in addition to 14 mL mixture of FII, FXIII, calcium, 
and Ringer’s Solution. 
Multi-Channel Liquid Fibrin Sealant Coated Carrier Foam Device 
 A multi-channel device was designed to delivery FS-coated carrier foam directly 
to the wound site using longer channels that mixed the FS components directly at the site 
of coating (Figure 8.1 F and 8.1G).  This device contains 8 staggered channels designed 
to mix of the fibrinogen with FXIII and FII on the carrier foam inside a beveled tip of the 
device.  This bevel applies minimal compaction to the foam while preventing the FS from 
being sprayed into the wound site.  Large channels of the device are designed to carry 
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highly viscous fibrinogen at the same rates as lower viscosity FXIII and FII in the smaller 
tubes. A second set of reservoirs for FS was also constructed to allow the use two 45 mL 
tubes instead of the previous 15 mL tubes. 
 
8.4 Results and Discussion 
Liquid Fibrin Sealant Coated Carrier Foam Device  
 The FS-coated carrier device proved to be an adequate device for applying the 
materials to the wound site.  However, several technical problems prevented significant 
study of this device.  The foremost issue was the mixing of the FS inside of the device, 
resulting in clot formation inside the nozzle that prevented the material from coating the 
carrier foam.  FS also tended to unequally coat the bottom side of the foam due to 
gravitational effects.  Additionally, while the short nozzle proved effective for coating the 
foam in vitro, the device ultimately proved difficult to position in the surgical theatre and 
unable to penetrate deep enough into the abdominal cavity to reliably deliver the FS-
coated foam.  
Multi-Channel Liquid Fibrin Sealant Coated Carrier Foam Device 
 The multi-channel device fixed many of the issues that plagued the initial device.  
The longer nozzle allowed for easier manipulation and application of the foam directly to 
a desired location in the abdominal cavity (Fig. 8.2A).  The device also has minimal 
clotting issues as long as the delivery pressures of both the carrier foam and FS remain 
approximately the same.  In addition, a more consistent cyclical coating was applied due 
to the multiple channels. 
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 While the carrier foam is still in the process of being optimally designed by LNK 
Chemsolutions, two morphologies of FS coated alginate foam have been observed.  The 
first formulation conformed to the shape of the abdominal cavity and organs of the swine 
(Fig. 8.2 B).  This foam also demonstrated a decrease from 4 L of foam injected into the 
cavity to less than 1 L of foam removed from the cavity 60 minutes after injection.  This 
dissociation or compaction of foam proved insufficient for maintaining a tamponade 
effect at the injury site.  A second formulation containing an increased percentage of 
alginate was formulated and provided a “tofu-like” morphology that maintained the 
tamponade effect for three hours (Fig. 8.2C) 
 The application of FS coated carrier foam in preclinical trials did not present with 
unqualified success.  The current version of the device has had 8 preclinical trials, 50% 
which survived for at least 1 hour, however, 37.5% of the swine presented with either a 
foam or clot obstruction in the heart (Fig. 8.3), and one swine did not respond to 
treatment.  Compared to a 60% survival rate in control surgeries, it is clear that more 
work must be done to ensure that the treatment is not riskier than the injury alone.  
However, post-mortem analysis of the livers of some surviving pigs (Fig. 8.4) indicates 
the goal of forming a clot around the wound site while applying a tamponade effect to 
prevent further bleeding is obtainable. 
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Figure 8.2. Delivery of fibrin sealant coated carrier foam to a swine abdominal cavity.  Injection of the 
foam 30 seconds after liver resection. B) Swine abdominal cavity one hour after administration of first 





Figure 8.3. Formation of blockages in the heart of swine.  A) Blockage formed by clotting factors and 
endogenous blood. B) Blockage formed by FS coated carrier foam. 
 
 
Figure 8.4. Post-mortem analysis of hepatic resection.  FS coated carrier foam was delivered to the 
swine abdominal cavity after hepatic resection.  The swine survived for the one-hour observation period. A) 
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Post-mortem removal of the liver revealed the presence of clot at the site of the hepatic resection. B) After 
removal of the clot at the site of the liver, the portal vein branch to the left lateral lobe and C) hepatic vein 
were confirmed to be transected. 
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Chapter 9:         
Future Work 
 
9.1 Preclinical Trials of r-FXIIIA1a for Topical Use alongside Commercial 
Coagulation Proteins 
 Intravenous administration of activated coagulation factors has recently become 
an issue of concern after factor VIIa was found to be linked to adverse thrombotic events 
[1].  However, r-FXIIIA1a still has numerous applications as a topical treatment in 
conjunction with other proteins.  Treatments for burns [2], venous ulcers [3], and 
lacerations [4, 5] all have the potential to benefit from a topical FXIII.  The lack of an 
activation lag for r-FXIIIA1a, as discussed in Chapter 2, allows for treatments to be 
effective in a small time frame.  A preclinical trial designed to test r-FXIIIa alone, in 
conjecture with commercial r-FIIa, and with commercial fibrin sealant for treatment of 
the above mentioned ailments in mice would be the ideal next step for this protein. 
 
9.2 Future Animal Models for Study of the Reservoir Phenomena of FIX 
 The reservoir phenomena of FIX have been indirectly characterized by the 
pharmacokinetic studies detailed in Chapters 4-6; however direct measurements of FIX 
storage in the extravascular reservoirs will be necessary in order to change the modern 
perception of hemophilia treatment.  Preclinical trials in mice where histological data of 
the extravascular matrix is assayed using anti-FIX antibodies will be the next necessary 
step in the research.  The histology will have to take into account both transport and 
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sequestration phenomena by taking multiple samples at set linear venous distances from 
the injection site.  The research of Dr. Stern must also be considered during this trial, 
where bovine FIX was shown to have stronger affinity for the endothelium of baboon 
than baboon FIX [6], as the affinity of human tg-FIX for the extravascular matrix of mice 
may be different than the affinity of human tg-FIX for the extravascular matrix of 
humans. 
 
9.3 Transgenically Modified Swine expressing VKOR and FIX 
One of the few issues with current tg-FIX is that a considerable portion of the FIX 
is under-carboxylated [7, 8].  Under-carboxylated factor IX is both less active and cleared 
more rapidly from the bloodstream than factor IX [9].  Vitamin K epoxide reductase 
(VKOR ) plays a role in carboxylation by recycling vitamin K [10-13]. By the addition of 
a VKOR to a site that produces FIX, a supply of active vitamin K can be maintained [14].   
Studies in baby hamster kidney cells [15] and in mice [16] have previously established 
that the addition of VKOR to a construct is capable of enhancing the correct production 
of VKD proteins. The addition of the VKOR construct to our mammary gland ensures 
that less under-carboxylated FIX is produced, ensuring a higher-throughput of fully 
formed FIX.  As the mammary gland is not known for producing an excess of VKOR, we 
have designed a this new swine construct using methods similar to Chauhan et al. [17] to 
express FIX and VKOR simultaneously, shown in Figure 9.1.   In December 2012, two 
different lineages of the bigenic FIX/VKOR pigs were born, each containing one female 
pig; however, neither lineage survived long enough to be bred.  A new construct has been 
built and will be used for future pigs.  By purifying and analyzing the bigenic milk from 
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these new animals, a more consistently γ-carboxylated version of FIX will be purified, 
characterized, and formulated [18] for delivery. 
 
Figure 9.1. FIX and VKOR construct layout for bigenic swine [19]. 
 
9.4 Characterization of the Gla domain for pd-FIX, r-FIX, and tg-FIX 
The methodology and equipment for mass spectrometry has advanced in recent 
years, and the recent acquisition of a new tandem mass spectrometer by the University of 
Nebraska Beadle Center should open up the opportunity for a collaboration between the 
department of chemical and biomolecular engineering and the department of 
biochemistry to characterize the Gla domain of factor IX.  This will allow the 
identification of the missing γ-carboxylation sites in both tg-FIX and r-FIX; which were 
identified in Chapter 5 as between Gla 7-10 for tg-FIX and between 11 and 12 for r-FIX 
[7].  In addition, using metal-dependent Gla domain antibodies in combination with mass 
spectrometry and Biacore, it will be possible to isolate species of FIX missing specific 
Gla residues, identify the missing residue using mass spectrometry, and identify the 
influence of specific Gla residues collagen binding.  These studies will also help fully 
characterize the binding cite of the 1G7 mAb described in Chapter 5, and has the 
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potential to further characterize antibodies such as the Toomey [20] and Bajaj [21] 
antibodies. 
 
9.5 Continued Progress in the Preclinical Trials of Liquid Fibrin Sealant 
 Preclinical trials for our FS have surpassed over 200 swine.  However, due to 
supply issues, most of these trials have used r-FIIa, r-FXIIIa, and pd-FI.  With the recent 
acquisition of the tg-FI producing cattle by LFB, it is likely that a supply of tg-FI will be 
available for future preclinical trials.  Previous research by our group has already 
demonstrated a drastic visible difference between FS containing pd-FI and tg-FI, and 
future long-term survival studies and histology will be needed in order to confirm that tg-
FI promotes wound healing in a comparable manner to pd-FI in vivo. In addition, the use 
of FS with carrier foam continues to be developed in collaboration with LNK.  FS will 
need to be re-optimized for new prototype devices, new bio-absorbable polymers, and 
final concentrations to maximize wound sealing properties, bio-absorption, and 
promotion of native cells.  Preclinical studies of the addition of fibronectin to FS will also 
need to be resumed during the survival studies in order assess changes in healing.  
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